A Dose Escalation and Expansion Study of Lomvastomig, a P... | NCT03708328 | Trialant
NCT03708328
Sponsor
Hoffmann-La Roche
Status
Completed
Last Update Posted
Aug 20, 2025Actual
Enrollment
134Actual
Phase
Phase 1
Conditions
Solid Tumors
Metastatic Melanoma
Non-small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
Lomvastomig
Countries
United States
Denmark
France
New Zealand
South Korea
Spain
Protocol Section
Identification Module
NCT ID
NCT03708328
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
NP40435
Secondary IDs
ID
Type
Description
Link
2018-000982-35
EudraCT Number
Brief Title
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Official Title
An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors
Acronym
Not provided
Organization
Hoffmann-La RocheINDUSTRY
Status Module
Record Verification Date
Aug 2025
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Oct 15, 2018Actual
Primary Completion Date
Jul 9, 2024Actual
Completion Date
Jul 9, 2024Actual
First Submitted Date
Oct 9, 2018
First Submission Date that Met QC Criteria
Oct 12, 2018
First Posted Date
Oct 17, 2018Actual
Results Waived
Not provided
Results First Submitted Date
Jul 7, 2025
Results First Submitted that Met QC Criteria
Aug 5, 2025
Results First Posted Date
Aug 20, 2025Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
Aug 5, 2025
Last Update Posted Date
Aug 20, 2025Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
Hoffmann-La RocheINDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
No
Is FDA Regulated Drug
Yes
Is FDA Regulated Device
No
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of single agent lomvastomig (RO7121661), an anti PD-1 (programmed death-1) and TIM-3 (T-cell immunoglobulin and mucin domain 3) bispecific antibody, for participants with advanced and/or metastatic solid tumors. The study consists of 2 parts: Dose Escalation (Part A) and Expansion (Parts B1, B2, B3, B4, and B5). The Dose Escalation part will be conducted first to determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) based on safety, tolerability, pharmacokinetic, and/or the pharmacodynamic profile of escalating doses of lomvastomig. The Expansion part will enroll tumor-specific cohorts to evaluate anti-tumor activity of the MTD and/or RDE of lomvastomig from Part A (Q2W) and to confirm safety and tolerability in participants with selected tumor types.
Detailed Description
Not provided
Conditions Module
Conditions
Solid Tumors
Metastatic Melanoma
Non-small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Esophageal Squamous Cell Carcinoma (ESCC)
Keywords
Not provided
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 1
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
134Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
Dose Escalation Part A: Once Every 2 Weeks (Q2W)
Experimental
Lomvastomig will be administered in treatment cycles once every 2 weeks (Q2W). Dose escalation will be carried out according to a modified continual reassessment method (mCRM) with escalation with overdose control (EWOC) design.
Drug: Lomvastomig
Expansion Part B1: Metastatic Melanoma Cohort
Experimental
This cohort will comprise participants with checkpoint inhibitor (CPI) experienced, second line and beyond metastatic melanoma. The starting dose of lomvastomig for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
Drug: Lomvastomig
Expansion Part B2: NSCLC Cohort 1
Experimental
This cohort will comprise participants with CPI and platinum experienced, second or third line PD-L1 positive non-small cell lung cancer (NSCLC). The starting dose of lomvastomig for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
Drug: Lomvastomig
Expansion Part B3: NSCLC Cohort 2
Experimental
This cohort will comprise participants with PD-L1 high, cancer immunotherapy (CIT) naïve first line NSCLC. The starting dose of lomvastomig for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
This cohort was not initiated and no participants were enrolled in it.
Interventions
Name
Type
Description
Arm Group Labels
Other Names
Lomvastomig
Drug
Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.
Dose Escalation Part A: Once Every 2 Weeks (Q2W)
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Part A: Number of Participants With a Dose-Limiting Toxicity (DLT)
A DLT was defined as a clinically significant adverse event (AE) or significant laboratory abnormality: 1) occurring during DLT assessment period of 21 days; 2) considered to be related to study treatment RO7121661 by the Investigator; 3) is not attributed to disease progression or another clearly identifiable cause. Following AEs were considered DLTs: Hematological toxicities (Grade 4 neutropenia lasting >5 days, Grade ≥3 febrile neutropenia, Grade 4 thrombocytopenia lasting > 48 hours, Grade 3 thrombocytopenia associated with bleeding episodes, Grade 4 anemia, Grade ≥3 anemia with hemolysis); Non-hematological toxicity Grade ≥3 (Any Grade 3 immune-mediated AE, Grade 3 hyperbilirubinemia lasting for >48 hours/Grade 4 hyperbilirubinemia; Grade ≥3 aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevations with hyperbilirubinemia of Grade ≥2, Grade 4 AST or ALT elevations, Grade ≥3 nausea, vomiting, or diarrhea, Grade ≥3 non-hematological laboratory abnormality.
From Cycle 1 Day 1 to Cycle 2 Day 7 (Cycle length= 14 days)
Part A: Number of Participants With at Least One AE by Highest Severity, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
AE=any untoward medical occurrence in a participant administered a pharmaceutical product & which does not necessarily have a causal relationship with treatment & can therefore be any unfavorable & unintended sign (including abnormal laboratory values/abnormal clinical test results), symptoms/disease temporally associated with the use of pharmaceutical product, whether or not considered related to pharmaceutical product. Severity of AEs was graded as: Grade 1=Mild, asymptomatic/mild symptoms, clinical/diagnostic observations only, or intervention not indicated; Grade 2=Moderate, minimal, local/non-invasive intervention indicated, or limiting age-appropriate instrumental activities of daily living; Grade 3=Severe/medically significant but not immediately life-threatening, hospitalization/prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4= Life-threatening consequences, urgent intervention indicated; Grade 5=Death related to AE.
From signing of informed consent form up to 60 days after last treatment administration (up to 41.7 months)
Secondary Outcomes
Measure
Description
Time Frame
Parts A and B: Number of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs)
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following study drug administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such as at least 4-fold (treatment-enhanced ADA response).
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
General Inclusion Criteria:
Part A: Patient must have histologically or cytologically confirmed advanced and/or metastatic solid tumor malignancies for which standard curative or palliative measures do not exist, are no longer effective, or are not acceptable to the patient
Eastern Cooperative Oncology Group Performance Status 0-1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Fresh biopsies may be required
Negative HIV, hepatitis B, or hepatitis C test result
Women of childbearing potential and male participants must agree to remain abstinent or use contraceptive methods as defined by the protocol
Additional Specific Inclusion Criteria for Participants with Melanoma:
Histologically confirmed, unresectable stage III or stage IV melanoma
Previously treated with approved anti-programmed death-ligand 1 (PD-L1)/anti-programmed death-1 (PD-1) agents with or without approved anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) therapy and up to one additional treatment regimen
Additional Specific Inclusion Criteria for Participants with Non-small Cell Lung Cancer (NSCLC) who Previously Received Treatment for Metastatic Disease:
Histologically confirmed advanced NSCLC
Previously treated with approved PD-L1/PD-1 inhibitors and platinum-based chemotherapy
Not more than 2 prior lines of treatment for metastatic disease are allowed prior to enrolling to the study
Participants must have experienced initial clinical benefit (stable disease or better) from most recent checkpoint inhibitor (CPI) therapy
Tumor PD-L1 expression as determined by immunohistochemistry assay of archival tumor tissue or tissue obtained at screening
Additional Specific Inclusion Criteria for Participants with Non-small Cell Lung Cancer (NSCLC) who Previously Did Not Receive Treatment for Metastatic Disease:
Histologically confirmed advanced NSCLC
Tumor PD-L1 expression as determined by immunohistochemistry assay of archival tumor tissue or tissue obtained at screening
Additional Specific Inclusion Criteria for Participants with Small Cell Lung Cancer (SCLC):
Histologically confirmed SCLC
Participants may have had prior chemotherapy, radiation therapy, or declined approved therapies for SCLC
Additional Specific Inclusion Criteria for Participants with Esophageal Squamous Cell Carcinoma (ESCC):
Participants whose major lesion was histologically confirmed as squamous cell carcinoma or adenosquamous cell carcinoma of the esophagus
Patients who have previously received not more than 1 prior line of treatment for metastatic disease prior to enrolling to the study
Exclusion Criteria:
General Exclusion Criteria:
Pregnancy, lactation, or breastfeeding
Known hypersensitivity to any of the components of RO7121661
Active or untreated central nervous system (CNS) metastases
An active second malignancy
Evidence of concomitant diseases, metabolic dysfunction, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications
Known active or uncontrolled bacterial, viral, fungal, mycobacterial, parasitic, or other infection
Treatment with oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1
Active or history of autoimmune disease or immune deficiency
Prior treatment with adoptive cell therapies, such as CAR-T therapies
Concurrent therapy with any other investigational drug <28 days or 5 half-lives of the drug, whichever is shorter, prior to the first RO7247669 administration
Regular immunosuppressive therapy
Radiotherapy within the last 4 weeks before start of study drug treatment, with the exception of limited palliative radiotherapy
Prior treatment with a T-cell immunoglobulin and mucin domain-3 (TIM-3) inhibitor
Additional Specific Exclusion Criteria for Participants with NSCLC who Previously Received Treatment for Metastatic Disease:
- Patients with the following mutations, rearrangements, translocations are not eligible: epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK); ROS proto-oncogene 1 (ROS1), BRAFV600E, and neurotrophic receptor tyrosine kinase (NTRK)
Additional Specific Exclusion Criteria for Participants with NSCLC who Did Not Previously Receive Treatment for Metastatic Disease:
Prior therapy for metastatic disease
Adjuvant anti-PD-1 or anti-PD-L1 therapy
Additional Specific Exclusion Criteria for Participants with Small-Cell Lung Cancer (SCLC):
- Prior therapy with any immune CPIs (such as anti-PD-L1/PD-1, CTLA-4)
Additional Specific Exclusion Criteria for Participants with Esophageal Squamous Cell Carcinoma (ESCC):
Rohrberg KS, Melero I, F Sanmamed M, Munoz-Couselo E, Cervantes A, Gambardella V, Greillier L, Garrido P, Kim HR, Lee DH, Italiano A, Cassier PA, Hiret S, Deva S, Kim TM, Blumenschein GR Jr, Lovendahl Eefsen R, Henick BS, Perro M, Umana P, Peixoto A, Lauener L, Weber P, Seeber S, Klein C, Higgins B, Guidi M, Kraus D, Mucke M, Heichinger C, Tran VL, Schmid D, Michielin F, Liu T, McIntyre C, Kao H, Codarri Deak L, Markert C, Moreno V. First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors. J Immunother Cancer. 2026 Jun 19;14(6):e012729. doi: 10.1136/jitc-2025-012729.
See Also Links
Not provided
Available IPD Information
Not provided
IPD Sharing Statement Module
Plan to Share IPD
No
Description
Not provided
Types
Not provided
Time Frame
Not provided
Access Criteria
Not provided
URL
Not provided
Results Section
Participant Flow Module
Pre-assignment Details
This study was conducted in two parts: Part A (Dose Escalation) and Part B (Tumor-Specific Expansion Cohorts). Part B included the Cohorts B1, B2, B4, and B5, enrolling participants with selected tumor types. Part B3 was not initiated.
Recruitment Details
A total of 134 participants with advanced and/or metastatic solid tumors took part in the study across 17 investigative sites in Spain, France, Republic of Korea, Denmark, United States and New Zealand from 15 October 2018 to 09 July 2024.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
Part A: Lomvastomig 70 mg
Participants received 70 milligrams (mg) of lomvastomig, as an intravenous (IV) infusion on Cycle 1 Day 1 and every two weeks (Q2W) thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
FG001
Periods
Title
Milestones
Reasons Not Completed
Overall Study
Type
Comment
Milestone Data
STARTED
Baseline Characteristics Module
Baseline Analysis Population Description
Outcome Measures Module
Outcome Measures
Adverse Events Module
Frequency Threshold
5
More Info Module
Limitations and Caveats
Not provided
Annotation Section
No data available
No data is available for this block.
Document Section
Large Document Module
Document Has No Statistical Analysis Plan (SAP)
Not provided
Uploaded Document Information
Type
Includes Protocol
Includes SAP
Includes ICF
Document Label
Document Date
Document Uploaded Date
Document File Name
Prot_SAP
Yes
Yes
No
Study Protocol and Statistical Analysis Plan
Sep 7, 2021
Derived Section
Miscellaneous Info Module
Version Holder
Jul 10, 2026
Removed Countries
Netherlands
Submission Tracking
No data available
No data is available for this block.
Condition Browse Module
MeSH Terms
Intervention Browse Module
No data available
No data is available for this block.
Non-Randomized
Intervention Model
Sequential Assignment
Intervention Model Description
Not provided
Primary Purpose
Treatment
Observational Model
Not provided
Time Perspective
Not provided
Masking Info
Masking
None (Open Label)
Masking Description
Not provided
Who Masked
Not provided
Drug: Lomvastomig
Expansion Part B4: SCLC Cohort
Experimental
This cohort will comprise participants with CPI naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to, standard therapy. The starting dose of lomvastomig for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
Drug: Lomvastomig
Expansion Part B5: ESCC Cohort
Experimental
This cohort will comprise participants with CPI-naïve esophageal squamous cell carcinoma (ESCC). The starting dose of lomvastomig for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
Drug: Lomvastomig
Expansion Part B1: Metastatic Melanoma Cohort
Expansion Part B2: NSCLC Cohort 1
Expansion Part B3: NSCLC Cohort 2
Expansion Part B4: SCLC Cohort
Expansion Part B5: ESCC Cohort
RO7121661
RG7769
Part B: Objective Response Rate (ORR) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
ORR was defined as the percentage of participants with an objective tumor response of complete response (CR) or partial response (PR) as determined by the investigator using RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to <10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD.
Cycle 1 Day 1 then every 8 weeks for the first year; every 12 weeks thereafter until disease progression or treatment discontinuation (whichever occurs last), initiation of a new line of therapy or death (Up to 43.3 months) (Cycle length= 14 days)
Part B: Disease Control Rate (DCR) as Determined by Investigator Using RECIST v1.1
DCR was defined as the percentage of participants with an objective tumor response of CR, PR or stable disease (SD) as determined by the investigator using RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression (PD). PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Cycle 1 Day 1 then every 8 weeks for the first year; every 12 weeks thereafter until disease progression or treatment discontinuation (whichever occurs last), initiation of a new line of therapy or death (Up to 43.3 months) (Cycle length= 14 days)
Part B: Duration of Response (DOR) as Determined by Investigator Using RECIST v1.1
DOR was calculated for participants who had a best confirmed overall response (OR) of CR/PR. DOR was defined as time from first occurrence of a documented OR until the time of documented PD or death (within 30 days from last treatment) from any cause, whichever occurs first as determined by investigator assessment using RECIST v1.1. CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Data for participants without PD or death as of the data cut-off date were censored at the time of the last tumor assessment.
From first occurrence of documented OR up to disease progression or death (Up to 43.3 months) (Cycle length = 14 days)
Part B: Progression Free Survival (PFS) as Determined by Investigator Using RECIST v1.1
PFS was defined as the time from study treatment initiation (Cycle 1 Day 1) to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Data for participants without PD or death as of the data cut-off date were censored at the time of the last tumor assessment.
From treatment initiation (Cycle 1 Day 1) until disease progression or death (Up to 43.3 months) (Cycle length= 14 days)
Baseline and Day 1 of Cycles 1 to 5; Day 1 of Cycle 7, and every 6 cycles thereafter (1 cycle is 14 days); study completion/discontinuation; safety follow-up visits (up to approximately 40.8 months - Part A and 45.4 months - Part B)
Part B: Biomarkers: T-cell Proliferation/Activation in Peripheral Blood
Biomarker analyses were performed using peripheral blood samples that were collected from participants in Part B of the study. The blood samples were assessed by flow cytometry for absolute counts of CD3⁺CD8⁺ T cells and proliferating CD3⁺CD8⁺Ki67⁺ T cells.
Days 1, 2, and 8 of Cycles 1 and 5; Day 1 of Cycles 2, 3, and 9 (1 cycle is 14 days); study completion visit (28 days after last dose; up to 43.3 months); safety follow-up (SFU) (90 days after last dose; up to 45.4 months)
Part B: Biomarkers: CD8+ T-cell Densities in Tumor Biopsies
Fresh tumor biopsies were collected from participants in Part B of the study to assess changes in T-cell infiltration and activation within the tumor microenvironment. Tumor tissue was evaluated for CD8⁺ T-cell densities. The tumor tissue samples were collected at screening (archival metastasis and archival primary samples) and during the study (fresh samples).
At screening and Cycle 3 Day 1
Parts A and B: Time to Maximum Observed Serum Concentration (Tmax) of Lomvastomig
Predose, half infusion, end of infusion (EOI), 0.5, 2, 4, and 8 hours postdose on Cycle 1 Day 1 and Cycle 5 Day 1, and on Cycles 1 and 5 Days 2, 3, 4, 5, 8, and 12, and predose on Day 1 of Cycles 2 and 6 (1 cycle = 14 days)
Parts A and B: Maximum Observed Serum Concentration (Cmax) of Lomvastomig
Predose, half infusion, end of infusion (EOI), 0.5, 2, 4, and 8 hours postdose on Cycle 1 Day 1 and Cycle 5 Day 1, and on Cycles 1 and 5 Days 2, 3, 4, 5, 8, and 12, and predose on Day 1 of Cycles 2 and 6 (1 cycle = 14 days)
Parts A and B: Maximum Observed Serum Concentration Dose Normalized (Cmax_D) of Lomvastomig
Predose, half infusion, end of infusion (EOI), 0.5, 2, 4, and 8 hours postdose on Cycle 1 Day 1 and Cycle 5 Day 1, and on Cycles 1 and 5 Days 2, 3, 4, 5, 8, and 12, and predose on Day 1 of Cycles 2 and 6 (1 cycle = 14 days)
Parts A and B: Time to Last Non-zero Concentration (Tlast) of Lomvastomig
For participants who experienced an adverse event (AE) following infusion with lomvastomig, a delay of the next administration for up to two cycles was acceptable to allow for resolution of toxicity to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 2 or lower for hematological toxicities or Grade 1 or lower for non-hematological toxicities (with the exception of a toxicity considered as not related to study drug). In the case of a delayed administration, the predose PK sample for Day 1 of Cycles 2 and/or 6 could have been collected up to 28 days after the end of the previous treatment cycle.
Predose, half infusion, end of infusion (EOI), 0.5, 2, 4, and 8 hours postdose on Cycle 1 Day 1 and Cycle 5 Day 1, and on Cycles 1 and 5 Days 2, 3, 4, 5, 8, and 12, and predose on Day 1 of Cycles 2 and 6 (1 cycle = 14 days)
Parts A and B: Last Non-zero Concentration (Clast) of Lomvastomig
For participants who experienced an adverse event (AE) following infusion with lomvastomig, a delay of the next administration for up to two cycles was acceptable to allow for resolution of toxicity to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 2 or lower for hematological toxicities or Grade 1 or lower for non-hematological toxicities (with the exception of a toxicity considered as not related to study drug). In the case of a delayed administration, the predose PK sample for Day 1 of Cycles 2 and/or 6 could have been collected up to 28 days after the end of the previous treatment cycle.
Predose, half infusion, end of infusion (EOI), 0.5, 2, 4, and 8 hours postdose on Cycle 1 Day 1 and Cycle 5 Day 1, and on Cycles 1 and 5 Days 2, 3, 4, 5, 8, and 12, and predose on Day 1 of Cycles 2 and 6 (1 cycle = 14 days)
Parts A and B: Area Under the Curve From Dosing to Last Concentration (AUClast) of Lomvastomig
For participants who experienced an adverse event (AE) following infusion with lomvastomig, a delay of the next administration for up to two cycles was acceptable to allow for resolution of toxicity to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 2 or lower for hematological toxicities or Grade 1 or lower for non-hematological toxicities (with the exception of a toxicity considered as not related to study drug). In the case of a delayed administration, the predose PK sample for Day 1 of Cycles 2 and/or 6 could have been collected up to 28 days after the end of the previous treatment cycle.
Predose, half infusion, end of infusion (EOI), 0.5, 2, 4, and 8 hours postdose on Cycle 1 Day 1 and Cycle 5 Day 1, and on Cycles 1 and 5 Days 2, 3, 4, 5, 8, and 12, and predose on Day 1 of Cycles 2 and 6 (1 cycle = 14 days)
Parts A and B: Area Under the Curve From Dosing to 336 Hours Post-dose (AUC0-336 Hrs) of Lomvastomig
Predose, half infusion, end of infusion (EOI), 0.5, 2, 4, and 8 hours postdose on Cycle 1 Day 1 and Cycle 5 Day 1, and on Cycles 1 and 5 Days 2, 3, 4, 5, 8, and 12, and predose on Day 1 of Cycles 2 and 6 (1 cycle = 14 days)
Part A: Receptor Occupancy (RO) of Lomvastomig, Assessed Via an Ex-Vivo Assay
Blood samples were collected from participants in Part A of the study and different types of immune cells were assessed by flow cytometry for the percentage of receptor occupancy (RO) by lomvastomig. RO (or drug coverage) is used to quantify the binding of the therapeutic to its target on the cell surface. The RO of lomvastomig was determined on cells that were positive (+) for CD3+, CD4+, CD56+/16+, and CD8+.
Predose and EOI: Day 1 of Cycles 1 and 5; Predose: Day 1 of Cycles 2, 3, and 9; Postdose: Day 8 of Cycles 1 and 5 (1 cycle is 14 days); study completion (28 days after last dose; up to 39.7 months); SFU (60 days after last dose; up to 40.8 months)
Part B: Number of Participants With at Least One AE by Highest Severity, Graded According to the NCI CTCAE v5.0
AE=any untoward medical occurrence in a participant administered a pharmaceutical product & which does not necessarily have a causal relationship with treatment & can therefore be any unfavorable & unintended sign (including abnormal laboratory values/abnormal clinical test results), symptoms/disease temporally associated with the use of pharmaceutical product, whether or not considered related to pharmaceutical product. Severity of AEs was graded as: Grade 1=Mild, asymptomatic/mild symptoms, clinical/diagnostic observations only, or intervention not indicated; Grade 2=Moderate, minimal, local/non-invasive intervention indicated, or limiting age-appropriate instrumental activities of daily living; Grade 3=Severe/medically significant but not immediately life-threatening, hospitalization/prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4= Life-threatening consequences, urgent intervention indicated; Grade 5=Death related to AE.
From signing of informed consent form up to 90 days after last treatment administration (up to 46.2 months)
Part A: ORR as Determined by Investigator Using RECIST v1.1
ORR was defined as the percentage of participants with an objective tumor response of CR or PR as determined by the investigator using RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD.
Cycle 1 Day 1 then every 8 weeks for the first year; every 12 weeks thereafter until disease progression or treatment discontinuation (whichever occurs last), initiation of a new line of therapy or death (Up to 39.7 months) (Cycle length= 14 days)
Part A: DCR as Determined by Investigator Using RECIST v1.1
DCR was defined as the percentage of participants with an objective tumor response of CR, PR or SD as determined by the investigator using RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Cycle 1 Day 1 then every 8 weeks for the first year; every 12 weeks thereafter until disease progression or treatment discontinuation (whichever occurs last), initiation of a new line of therapy or death (Up to 39.7 months) (Cycle length= 14 days)
Part A: DOR as Determined by Investigator Using RECIST v1.1
DOR was calculated for participants who had a best confirmed OR of CR/PR. DOR was defined as time from first occurrence of a documented OR until the time of documented PD or death from any cause, whichever occurs first as determined by investigator assessment using RECIST v1.1. CR=the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to <10 mm. PR=at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD=at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Data for participants without PD or death from any cause as of the data cut-off date were censored at the time of the last tumor assessment.
From first occurrence of documented OR up to disease progression or death (Up to 39.7 months) (Cycle length= 14 days)
Part A: PFS as Determined by Investigator Using RECIST v1.1
PFS was defined as the time from study treatment initiation (Cycle 1 Day 1) to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Data for participants without PD or death as of the data cut-off date were censored at the time of the last tumor assessment.
From initiation of study treatment (Cycle 1 Day 1) until disease progression or death (Up to 39.7 months) (Cycle length= 14 days)
Houston
Texas
77030
United States
Herlev Hospital
Herlev
2730
Denmark
Rigshospitalet
København Ø
2100
Denmark
Institut Bergonie
Bordeaux
33076
France
Centre Leon Berard
Lyon
69008
France
CHU Timone
Marseille
13005
France
ICO Rene Gauducheau
Saint-Herblain
44805
France
Auckland City Hospital
Auckland
1023
New Zealand
Seoul National University Hospital
Seoul
03080
South Korea
Severance Hospital, Yonsei University Health System
Seoul
03722
South Korea
Asan Medical Center
Seoul
05505
South Korea
Clinica Universitaria de Navarra
Pamplona
Navarre
31008
Spain
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona
08035
Spain
Hospital Ramon y Cajal
Madrid
28034
Spain
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
Madrid
28040
Spain
Hospital Clínico Universitario de Valencia
Valencia
46010
Spain
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
FG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
FG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
FG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
FG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
FG006
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
FG007
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
FG008
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve SCLC with prior failure of, progression on, or intolerance to standard therapy received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
FG009
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve ESCC received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
FG0003 subjects
FG0015 subjects
FG0024 subjects
FG0034 subjects
FG0044 subjects
FG00519 subjects
FG00638 subjects
FG00726 subjects
FG00815 subjects
FG00916 subjects
COMPLETED
FG0000 subjects
FG0011 subjects
FG0020 subjects
FG0031 subjects
FG0041 subjects
FG0051 subjects
FG0067 subjects
FG0072 subjects
FG0080 subjects
FG0092 subjects
NOT COMPLETED
FG0003 subjects
FG0014 subjects
FG0024 subjects
FG0033 subjects
FG0043 subjects
FG00518 subjects
FG00631 subjects
FG00724 subjects
FG00815 subjects
FG00914 subjects
Type
Comment
Reasons
Death
FG0003 subjects
FG0013 subjects
FG0024 subjects
FG0032 subjects
FG0042 subjects
FG00513 subjects
FG00626 subjects
FG00718 subjects
FG00813 subjects
FG0098 subjects
Lost to Follow-up
FG0000 subjects
FG0011 subjects
FG0020 subjects
FG0031 subjects
FG004
Physician Decision
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Withdrawal by Subject
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Study Closed Locally
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Study Ended By Sponsor
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Participant Was Alive, Did Not Return to Hospital
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
Safety population included all participants who received at least one dose of the study treatment, whether prematurely withdrawn from the study or not.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
BG001
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
BG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
BG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
BG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
BG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
BG006
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
BG007
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
BG008
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve SCLC with prior failure of, progression on, or intolerance to standard therapy received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
BG009
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve ESCC received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
BG010
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG0003
BG0015
BG0024
BG0034
BG0044
BG00519
BG00638
BG00726
BG00815
BG00916
BG010134
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Standard Deviation
years
Title
Denominators
Categories
Title
Measurements
BG00056.3± 9.3
BG00159.6± 13.9
BG00261.0± 2.4
BG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG0001
BG0011
BG002
Ethnicity (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Hispanic or Latino
BG0001
BG0010
BG002
Race (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
American Indian or Alaska Native
BG0000
BG0010
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Part A: Number of Participants With a Dose-Limiting Toxicity (DLT)
A DLT was defined as a clinically significant adverse event (AE) or significant laboratory abnormality: 1) occurring during DLT assessment period of 21 days; 2) considered to be related to study treatment RO7121661 by the Investigator; 3) is not attributed to disease progression or another clearly identifiable cause. Following AEs were considered DLTs: Hematological toxicities (Grade 4 neutropenia lasting >5 days, Grade ≥3 febrile neutropenia, Grade 4 thrombocytopenia lasting > 48 hours, Grade 3 thrombocytopenia associated with bleeding episodes, Grade 4 anemia, Grade ≥3 anemia with hemolysis); Non-hematological toxicity Grade ≥3 (Any Grade 3 immune-mediated AE, Grade 3 hyperbilirubinemia lasting for >48 hours/Grade 4 hyperbilirubinemia; Grade ≥3 aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevations with hyperbilirubinemia of Grade ≥2, Grade 4 AST or ALT elevations, Grade ≥3 nausea, vomiting, or diarrhea, Grade ≥3 non-hematological laboratory abnormality.
The DLT-evaluable population included all participants in Part A who received at least two doses of study medication and either experienced a DLT within the DLT period or cleared the DLT period without a DLT.
Posted
Count of Participants
Participants
From Cycle 1 Day 1 to Cycle 2 Day 7 (Cycle length= 14 days)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0015
OG0024
OG003
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
OG0020
OG003
Primary
Part A: Number of Participants With at Least One AE by Highest Severity, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
AE=any untoward medical occurrence in a participant administered a pharmaceutical product & which does not necessarily have a causal relationship with treatment & can therefore be any unfavorable & unintended sign (including abnormal laboratory values/abnormal clinical test results), symptoms/disease temporally associated with the use of pharmaceutical product, whether or not considered related to pharmaceutical product. Severity of AEs was graded as: Grade 1=Mild, asymptomatic/mild symptoms, clinical/diagnostic observations only, or intervention not indicated; Grade 2=Moderate, minimal, local/non-invasive intervention indicated, or limiting age-appropriate instrumental activities of daily living; Grade 3=Severe/medically significant but not immediately life-threatening, hospitalization/prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4= Life-threatening consequences, urgent intervention indicated; Grade 5=Death related to AE.
Safety population included all participants who received at least one dose of the study treatment, whether prematurely withdrawn from the study or not.
Posted
Count of Participants
Participants
From signing of informed consent form up to 60 days after last treatment administration (up to 41.7 months)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Primary
Part B: Objective Response Rate (ORR) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
ORR was defined as the percentage of participants with an objective tumor response of complete response (CR) or partial response (PR) as determined by the investigator using RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to <10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD.
Efficacy population included all participants in the safety population who received at least one dose of study drug and who had at least one baseline and one on-study tumor assessment.
Posted
Number
90% Confidence Interval
percentage of participants
Cycle 1 Day 1 then every 8 weeks for the first year; every 12 weeks thereafter until disease progression or treatment discontinuation (whichever occurs last), initiation of a new line of therapy or death (Up to 43.3 months) (Cycle length= 14 days)
ID
Title
Description
OG000
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Part B2: NSCLC Expansion Cohort 1
Primary
Part B: Disease Control Rate (DCR) as Determined by Investigator Using RECIST v1.1
DCR was defined as the percentage of participants with an objective tumor response of CR, PR or stable disease (SD) as determined by the investigator using RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression (PD). PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Efficacy population included all participants in the safety population who received at least one dose of study drug and who had at least one baseline and one on-study tumor assessment.
Posted
Number
90% Confidence Interval
percentage of participants
Cycle 1 Day 1 then every 8 weeks for the first year; every 12 weeks thereafter until disease progression or treatment discontinuation (whichever occurs last), initiation of a new line of therapy or death (Up to 43.3 months) (Cycle length= 14 days)
ID
Title
Description
OG000
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Primary
Part B: Duration of Response (DOR) as Determined by Investigator Using RECIST v1.1
DOR was calculated for participants who had a best confirmed overall response (OR) of CR/PR. DOR was defined as time from first occurrence of a documented OR until the time of documented PD or death (within 30 days from last treatment) from any cause, whichever occurs first as determined by investigator assessment using RECIST v1.1. CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Data for participants without PD or death as of the data cut-off date were censored at the time of the last tumor assessment.
Efficacy population included all participants in the safety population who received at least one dose of study drug and who had at least one baseline and one on-study tumor assessment. Overall number analyzed is the number of participants with OR, i.e., responders.
Posted
Median
90% Confidence Interval
months
From first occurrence of documented OR up to disease progression or death (Up to 43.3 months) (Cycle length = 14 days)
ID
Title
Description
OG000
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Primary
Part B: Progression Free Survival (PFS) as Determined by Investigator Using RECIST v1.1
PFS was defined as the time from study treatment initiation (Cycle 1 Day 1) to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Data for participants without PD or death as of the data cut-off date were censored at the time of the last tumor assessment.
Efficacy population included all participants in the safety population who received at least one dose of study drug and who had at least one baseline and one on-study tumor assessment.
Posted
Median
90% Confidence Interval
months
From treatment initiation (Cycle 1 Day 1) until disease progression or death (Up to 43.3 months) (Cycle length= 14 days)
ID
Title
Description
OG000
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Part B2: NSCLC Expansion Cohort 1
Secondary
Parts A and B: Number of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs)
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following study drug administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such as at least 4-fold (treatment-enhanced ADA response).
Safety population included all participants who received at least one dose of the study treatment, whether prematurely withdrawn from the study or not. The number of participants analyzed for each group indicates the number of participants with an ADA assay result from at least one post-baseline sample.
Posted
Count of Participants
Participants
Baseline and Day 1 of Cycles 1 to 5; Day 1 of Cycle 7, and every 6 cycles thereafter (1 cycle is 14 days); study completion/discontinuation; safety follow-up visits (up to approximately 40.8 months - Part A and 45.4 months - Part B)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Secondary
Part B: Biomarkers: T-cell Proliferation/Activation in Peripheral Blood
Biomarker analyses were performed using peripheral blood samples that were collected from participants in Part B of the study. The blood samples were assessed by flow cytometry for absolute counts of CD3⁺CD8⁺ T cells and proliferating CD3⁺CD8⁺Ki67⁺ T cells.
The safety population included all participants who received at least one dose of the study treatment, whether prematurely withdrawn from the study or not. Overall number analyzed = participants with data available for analysis. Number analyzed = participants with data available for analysis at the specified timepoint.
Posted
Mean
Standard Deviation
cells per microliter (cells/µL)
Days 1, 2, and 8 of Cycles 1 and 5; Day 1 of Cycles 2, 3, and 9 (1 cycle is 14 days); study completion visit (28 days after last dose; up to 43.3 months); safety follow-up (SFU) (90 days after last dose; up to 45.4 months)
ID
Title
Description
OG000
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Secondary
Part B: Biomarkers: CD8+ T-cell Densities in Tumor Biopsies
Fresh tumor biopsies were collected from participants in Part B of the study to assess changes in T-cell infiltration and activation within the tumor microenvironment. Tumor tissue was evaluated for CD8⁺ T-cell densities. The tumor tissue samples were collected at screening (archival metastasis and archival primary samples) and during the study (fresh samples).
Safety population included all participants who received at least one dose of the study treatment, whether prematurely withdrawn from the study or not. Overall number analyzed = participants with data available for analysis. Number analyzed=number of participants with data available for analysis at the specified timepoint.
Posted
Mean
Standard Deviation
cells per millimetre square (cells/mm^2)
At screening and Cycle 3 Day 1
ID
Title
Description
OG000
Part B1: Metastatic Melanoma Expansion Cohort
Participants with CPI experienced second line and beyond metastatic melanoma received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line PD-L1 positive NSCLC received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Secondary
Parts A and B: Time to Maximum Observed Serum Concentration (Tmax) of Lomvastomig
Pharmacokinetic (PK) population included all participants who have received at least one dose of study treatment and who have data from at least one post-dose sample. Overall number analyzed = participants with data available for analysis. Number analyzed = participants with data available for analysis at the specified timepoint.
Posted
Median
Full Range
days
Predose, half infusion, end of infusion (EOI), 0.5, 2, 4, and 8 hours postdose on Cycle 1 Day 1 and Cycle 5 Day 1, and on Cycles 1 and 5 Days 2, 3, 4, 5, 8, and 12, and predose on Day 1 of Cycles 2 and 6 (1 cycle = 14 days)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Secondary
Parts A and B: Maximum Observed Serum Concentration (Cmax) of Lomvastomig
PK population included all participants who have received at least one dose of study treatment and who have data from at least one post-dose sample. Overall number analyzed = participants with data available for analysis. Number analyzed = participants with data available for analysis at the specified timepoint.
Posted
Geometric Mean
Geometric Coefficient of Variation
micrograms/milliliters (µg/mL)
Predose, half infusion, end of infusion (EOI), 0.5, 2, 4, and 8 hours postdose on Cycle 1 Day 1 and Cycle 5 Day 1, and on Cycles 1 and 5 Days 2, 3, 4, 5, 8, and 12, and predose on Day 1 of Cycles 2 and 6 (1 cycle = 14 days)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part A: Lomvastomig 615 mg
Secondary
Parts A and B: Maximum Observed Serum Concentration Dose Normalized (Cmax_D) of Lomvastomig
PK population included all participants who have received at least one dose of study treatment and who have data from at least one post-dose sample. Overall number analyzed = participants with data available for analysis. Number analyzed = participants with data available for analysis at the specified timepoint.
Posted
Geometric Mean
Geometric Coefficient of Variation
microgram/milliliter/milligram(µg/mL/mg)
Predose, half infusion, end of infusion (EOI), 0.5, 2, 4, and 8 hours postdose on Cycle 1 Day 1 and Cycle 5 Day 1, and on Cycles 1 and 5 Days 2, 3, 4, 5, 8, and 12, and predose on Day 1 of Cycles 2 and 6 (1 cycle = 14 days)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part A: Lomvastomig 615 mg
Secondary
Parts A and B: Time to Last Non-zero Concentration (Tlast) of Lomvastomig
For participants who experienced an adverse event (AE) following infusion with lomvastomig, a delay of the next administration for up to two cycles was acceptable to allow for resolution of toxicity to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 2 or lower for hematological toxicities or Grade 1 or lower for non-hematological toxicities (with the exception of a toxicity considered as not related to study drug). In the case of a delayed administration, the predose PK sample for Day 1 of Cycles 2 and/or 6 could have been collected up to 28 days after the end of the previous treatment cycle.
PK population included all participants who have received at least one dose of study treatment and who have data from at least one post-dose sample. Overall number analyzed = participants with data available for analysis. Number analyzed = participants with data available for analysis at the specified timepoint.
Posted
Median
Full Range
days
Predose, half infusion, end of infusion (EOI), 0.5, 2, 4, and 8 hours postdose on Cycle 1 Day 1 and Cycle 5 Day 1, and on Cycles 1 and 5 Days 2, 3, 4, 5, 8, and 12, and predose on Day 1 of Cycles 2 and 6 (1 cycle = 14 days)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Secondary
Parts A and B: Last Non-zero Concentration (Clast) of Lomvastomig
For participants who experienced an adverse event (AE) following infusion with lomvastomig, a delay of the next administration for up to two cycles was acceptable to allow for resolution of toxicity to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 2 or lower for hematological toxicities or Grade 1 or lower for non-hematological toxicities (with the exception of a toxicity considered as not related to study drug). In the case of a delayed administration, the predose PK sample for Day 1 of Cycles 2 and/or 6 could have been collected up to 28 days after the end of the previous treatment cycle.
PK population included all participants who have received at least one dose of study treatment and who have data from at least one post-dose sample. Overall number analyzed = participants with data available for analysis. Number analyzed = participants with data available for analysis at the specified timepoint.
Posted
Geometric Mean
Geometric Coefficient of Variation
µg/mL
Predose, half infusion, end of infusion (EOI), 0.5, 2, 4, and 8 hours postdose on Cycle 1 Day 1 and Cycle 5 Day 1, and on Cycles 1 and 5 Days 2, 3, 4, 5, 8, and 12, and predose on Day 1 of Cycles 2 and 6 (1 cycle = 14 days)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Secondary
Parts A and B: Area Under the Curve From Dosing to Last Concentration (AUClast) of Lomvastomig
For participants who experienced an adverse event (AE) following infusion with lomvastomig, a delay of the next administration for up to two cycles was acceptable to allow for resolution of toxicity to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 2 or lower for hematological toxicities or Grade 1 or lower for non-hematological toxicities (with the exception of a toxicity considered as not related to study drug). In the case of a delayed administration, the predose PK sample for Day 1 of Cycles 2 and/or 6 could have been collected up to 28 days after the end of the previous treatment cycle.
PK population included all participants who have received at least one dose of study treatment and who have data from at least one post-dose sample. Overall number analyzed = participants with data available for analysis. Number analyzed = participants with data available for analysis at the specified timepoint.
Posted
Geometric Mean
Geometric Coefficient of Variation
day*micrograms/milliliters (day*µg/mL)
Predose, half infusion, end of infusion (EOI), 0.5, 2, 4, and 8 hours postdose on Cycle 1 Day 1 and Cycle 5 Day 1, and on Cycles 1 and 5 Days 2, 3, 4, 5, 8, and 12, and predose on Day 1 of Cycles 2 and 6 (1 cycle = 14 days)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Secondary
Parts A and B: Area Under the Curve From Dosing to 336 Hours Post-dose (AUC0-336 Hrs) of Lomvastomig
PK population included all participants who have received at least one dose of study treatment and who have data from at least one post-dose sample. Overall number analyzed = participants with data available for analysis. Number analyzed = participants with data available for analysis at the specified timepoint.
Posted
Geometric Mean
Geometric Coefficient of Variation
day*µg/mL
Predose, half infusion, end of infusion (EOI), 0.5, 2, 4, and 8 hours postdose on Cycle 1 Day 1 and Cycle 5 Day 1, and on Cycles 1 and 5 Days 2, 3, 4, 5, 8, and 12, and predose on Day 1 of Cycles 2 and 6 (1 cycle = 14 days)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part A: Lomvastomig 615 mg
Secondary
Part A: Receptor Occupancy (RO) of Lomvastomig, Assessed Via an Ex-Vivo Assay
Blood samples were collected from participants in Part A of the study and different types of immune cells were assessed by flow cytometry for the percentage of receptor occupancy (RO) by lomvastomig. RO (or drug coverage) is used to quantify the binding of the therapeutic to its target on the cell surface. The RO of lomvastomig was determined on cells that were positive (+) for CD3+, CD4+, CD56+/16+, and CD8+.
Safety population included all participants who received at least one dose of the study treatment, whether prematurely withdrawn from the study or not. Overall number analyzed = participants with data available for analysis. Number analyzed = participants with data available for analysis at the specified timepoint.
Posted
Mean
Standard Deviation
percent occupancy
Predose and EOI: Day 1 of Cycles 1 and 5; Predose: Day 1 of Cycles 2, 3, and 9; Postdose: Day 8 of Cycles 1 and 5 (1 cycle is 14 days); study completion (28 days after last dose; up to 39.7 months); SFU (60 days after last dose; up to 40.8 months)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Secondary
Part B: Number of Participants With at Least One AE by Highest Severity, Graded According to the NCI CTCAE v5.0
AE=any untoward medical occurrence in a participant administered a pharmaceutical product & which does not necessarily have a causal relationship with treatment & can therefore be any unfavorable & unintended sign (including abnormal laboratory values/abnormal clinical test results), symptoms/disease temporally associated with the use of pharmaceutical product, whether or not considered related to pharmaceutical product. Severity of AEs was graded as: Grade 1=Mild, asymptomatic/mild symptoms, clinical/diagnostic observations only, or intervention not indicated; Grade 2=Moderate, minimal, local/non-invasive intervention indicated, or limiting age-appropriate instrumental activities of daily living; Grade 3=Severe/medically significant but not immediately life-threatening, hospitalization/prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4= Life-threatening consequences, urgent intervention indicated; Grade 5=Death related to AE.
Safety population included all participants who received at least one dose of the study treatment, whether prematurely withdrawn from the study or not.
Posted
Count of Participants
Participants
From signing of informed consent form up to 90 days after last treatment administration (up to 46.2 months)
ID
Title
Description
OG000
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Secondary
Part A: ORR as Determined by Investigator Using RECIST v1.1
ORR was defined as the percentage of participants with an objective tumor response of CR or PR as determined by the investigator using RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD.
Efficacy population included all participants in the safety population who received at least one dose of study drug and who had at least one baseline and one on-study tumor assessment.
Posted
Number
90% Confidence Interval
percentage of participants
Cycle 1 Day 1 then every 8 weeks for the first year; every 12 weeks thereafter until disease progression or treatment discontinuation (whichever occurs last), initiation of a new line of therapy or death (Up to 39.7 months) (Cycle length= 14 days)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Secondary
Part A: DCR as Determined by Investigator Using RECIST v1.1
DCR was defined as the percentage of participants with an objective tumor response of CR, PR or SD as determined by the investigator using RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Efficacy population included all participants in the safety population who received at least one dose of study drug and who had at least one baseline and one on-study tumor assessment.
Posted
Number
90% Confidence Interval
percentage of participants
Cycle 1 Day 1 then every 8 weeks for the first year; every 12 weeks thereafter until disease progression or treatment discontinuation (whichever occurs last), initiation of a new line of therapy or death (Up to 39.7 months) (Cycle length= 14 days)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Secondary
Part A: DOR as Determined by Investigator Using RECIST v1.1
DOR was calculated for participants who had a best confirmed OR of CR/PR. DOR was defined as time from first occurrence of a documented OR until the time of documented PD or death from any cause, whichever occurs first as determined by investigator assessment using RECIST v1.1. CR=the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to <10 mm. PR=at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD=at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Data for participants without PD or death from any cause as of the data cut-off date were censored at the time of the last tumor assessment.
Efficacy population included participants in the safety population who received at least one dose of study drug and who had at least one baseline and one on-study tumor assessment. Overall number analyzed included participants with OR i.e., responders.
Posted
Median
90% Confidence Interval
months
From first occurrence of documented OR up to disease progression or death (Up to 39.7 months) (Cycle length= 14 days)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Secondary
Part A: PFS as Determined by Investigator Using RECIST v1.1
PFS was defined as the time from study treatment initiation (Cycle 1 Day 1) to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Data for participants without PD or death as of the data cut-off date were censored at the time of the last tumor assessment.
Efficacy population included all participants in the safety population who received at least one dose of study drug and who had at least one baseline and one on-study tumor assessment.
Posted
Median
90% Confidence Interval
months
From initiation of study treatment (Cycle 1 Day 1) until disease progression or death (Up to 39.7 months) (Cycle length= 14 days)
ID
Title
Description
OG000
Part A: Lomvastomig 70 mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG001
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Time Frame
Part A: From signing of informed consent form up to 60 days after last treatment administration (up to 41.7 months); Part B: From signing of informed consent form up to 90 days after last treatment administration (up to 46.2 months)
Description
Safety population included all participants who received at least one dose of the study treatment, whether prematurely withdrawn from the study or not.
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Part A: Lomvastomig 70mg
Participants received 70 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
3
3
1
3
3
3
EG001
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
3
5
1
5
5
5
EG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
4
4
1
4
4
4
EG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
2
4
1
4
4
4
EG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
2
4
1
4
3
4
EG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
13
19
7
19
17
19
EG006
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
26
38
6
38
34
38
EG007
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
18
26
8
26
24
26
EG008
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve SCLC with prior failure of, progression on, or intolerance to standard therapy received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
13
15
4
15
15
15
EG009
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve ESCC received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
8
16
10
16
16
16
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Anaemia
Blood and lymphatic system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG0030 events0 affected4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0062 events2 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
Atrial fibrillation
Cardiac disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Retinopathy
Eye disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Abdominal pain
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Colitis
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Diarrhoea
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0012 events1 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Dysphagia
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Gastric haemorrhage
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Haematemesis
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Intestinal obstruction
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Obstruction gastric
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Oesophageal stenosis
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Small intestinal perforation
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Bile duct stenosis
Hepatobiliary disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Cholangitis
Hepatobiliary disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Cholecystitis
Hepatobiliary disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Appendicitis perforated
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Bronchitis
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Cellulitis
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Gallbladder abscess
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Phlebitis infective
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pneumonia
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Sepsis
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
False positive investigation result
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Haemoglobin decreased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Troponin T increased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Decreased appetite
Metabolism and nutrition disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Back pain
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Immune-mediated myositis
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Musculoskeletal pain
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Neck pain
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pain in extremity
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Cerebrovascular accident
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
VIth nerve paralysis
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Suicide attempt
Psychiatric disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Acute kidney injury
Renal and urinary disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Bronchospasm
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Chronic obstructive pulmonary disease
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Dyspnoea
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Haemoptysis
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Haemothorax
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pneumothorax
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pulmonary embolism
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pulmonary granuloma
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pulmonary haemorrhage
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Respiratory failure
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Embolism
Vascular disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hypertension
Vascular disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Internal haemorrhage
Vascular disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Anaemia
Blood and lymphatic system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0012 events1 affected5 at risk
EG0022 events1 affected4 at risk
EG0030 events0 affected4 at risk
EG0040 events0 affected4 at risk
EG00510 events6 affected19 at risk
EG0067 events5 affected38 at risk
EG0077 events6 affected26 at risk
EG0086 events5 affected15 at risk
EG0092 events2 affected16 at risk
Eosinophilia
Blood and lymphatic system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hyperleukocytosis
Blood and lymphatic system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Lymphopenia
Blood and lymphatic system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Neutropenia
Blood and lymphatic system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Thrombocytopenia
Blood and lymphatic system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Thrombocytosis
Blood and lymphatic system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Atrial fibrillation
Cardiac disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Atrioventricular block first degree
Cardiac disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Palpitations
Cardiac disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Sinus tachycardia
Cardiac disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Ventricular arrhythmia
Cardiac disorders
MedDRA 27.0
Systematic Assessment
EG0002 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Adrenal insufficiency
Endocrine disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hyperthyroidism
Endocrine disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hypothyroidism
Endocrine disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Thyroid disorder
Endocrine disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Diplopia
Eye disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Dry eye
Eye disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Visual impairment
Eye disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Abdominal distension
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Abdominal pain
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0012 events1 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Abdominal pain lower
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Abdominal pain upper
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Anal fissure
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Ascites
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Change of bowel habit
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Colitis
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Constipation
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0003 events2 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Diarrhoea
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0003 events2 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Dry mouth
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Dyspepsia
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Dysphagia
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Immune-mediated enterocolitis
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Nausea
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0005 events3 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Odynophagia
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Salivary hypersecretion
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Stomatitis
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Vomiting
Gastrointestinal disorders
MedDRA 27.0
Systematic Assessment
EG0003 events1 affected3 at risk
EG0012 events2 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Asthenia
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0022 events2 affected4 at risk
EG003
Chest pain
General disorders
MedDRA 27.0
Systematic Assessment
EG0002 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Chills
General disorders
MedDRA 27.0
Systematic Assessment
EG0002 events2 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Fatigue
General disorders
MedDRA 27.0
Systematic Assessment
EG0002 events2 affected3 at risk
EG0011 events1 affected5 at risk
EG0022 events2 affected4 at risk
EG003
Feeling cold
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Feeling hot
General disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Inflammation
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Influenza like illness
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Injection site reaction
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Malaise
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Medical device pain
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Mucosal inflammation
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Oedema
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Oedema peripheral
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pain
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pyrexia
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Secretion discharge
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Sluggishness
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Xerosis
General disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Cholestasis
Hepatobiliary disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
COVID-19
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Candida infection
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0002 events2 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Clostridium colitis
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Gingivitis
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Herpes virus infection
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Infection
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Nasopharyngitis
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pharyngitis
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pneumonia
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Respiratory tract infection
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Sinusitis
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Tooth infection
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Upper respiratory tract infection
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Accidental underdose
Injury, poisoning and procedural complications
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Infusion related reaction
Injury, poisoning and procedural complications
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Alanine aminotransferase increased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Aspartate aminotransferase increased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0022 events1 affected4 at risk
EG003
Blood alkaline phosphatase increased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Blood bilirubin increased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Blood creatine phosphokinase increased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Blood creatinine increased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Blood glucose increased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Blood lactate dehydrogenase increased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Blood thyroid stimulating hormone increased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
C-reactive protein increased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Electrocardiogram QT prolonged
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Gamma-glutamyltransferase increased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Glomerular filtration rate decreased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Haemoglobin decreased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Human chorionic gonadotropin increased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Neutrophil count decreased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Platelet count decreased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Protein total decreased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Troponin increased
Investigations
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Weight decreased
Investigations
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Decreased appetite
Metabolism and nutrition disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0011 events1 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Diabetes mellitus
Metabolism and nutrition disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hyperamylasaemia
Metabolism and nutrition disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Hypercalcaemia
Metabolism and nutrition disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hyperglycaemia
Metabolism and nutrition disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hyperkalaemia
Metabolism and nutrition disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hypoalbuminaemia
Metabolism and nutrition disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hypocalcaemia
Metabolism and nutrition disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hypokalaemia
Metabolism and nutrition disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hypomagnesaemia
Metabolism and nutrition disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hyponatraemia
Metabolism and nutrition disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hypophosphataemia
Metabolism and nutrition disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Increased appetite
Metabolism and nutrition disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Arthralgia
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0002 events2 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Arthritis
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Back pain
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0011 events1 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Flank pain
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Muscle spasms
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Muscular weakness
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Musculoskeletal chest pain
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Musculoskeletal pain
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Myalgia
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0002 events2 affected3 at risk
EG0012 events1 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Neck pain
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pain in extremity
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Sacral pain
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Tendon disorder
Musculoskeletal and connective tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Tumour pain
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Ageusia
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Dizziness
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Dysarthria
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Dysgeusia
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0004 events2 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Headache
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0003 events3 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hypoaesthesia
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hypokinesia
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Paraesthesia
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Peripheral sensory neuropathy
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Peroneal nerve palsy
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Post herpetic neuralgia
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Somnolence
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Syncope
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Taste disorder
Nervous system disorders
MedDRA 27.0
Systematic Assessment
EG0002 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Anxiety
Psychiatric disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Bradyphrenia
Psychiatric disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Depression
Psychiatric disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Insomnia
Psychiatric disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Restlessness
Psychiatric disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Haematuria
Renal and urinary disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Proteinuria
Renal and urinary disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Renal colic
Renal and urinary disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Vaginal discharge
Reproductive system and breast disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Chronic obstructive pulmonary disease
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Cough
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Dysphonia
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Dyspnoea
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0003 events2 affected3 at risk
EG0010 events0 affected5 at risk
EG0022 events2 affected4 at risk
EG003
Haemoptysis
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hiccups
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Lung disorder
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Oropharyngeal pain
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Painful respiration
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pleural effusion
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Productive cough
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pulmonary embolism
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pulmonary oedema
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pulmonary pain
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Respiratory distress
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Rhinorrhoea
Respiratory, thoracic and mediastinal disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Alopecia
Skin and subcutaneous tissue disorders
MedDRA 27.0
Systematic Assessment
EG0002 events2 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Dermatitis atopic
Skin and subcutaneous tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Dermatitis exfoliative generalised
Skin and subcutaneous tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Dry skin
Skin and subcutaneous tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Erythema
Skin and subcutaneous tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Nail disorder
Skin and subcutaneous tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Night sweats
Skin and subcutaneous tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Onychoclasis
Skin and subcutaneous tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Pruritus
Skin and subcutaneous tissue disorders
MedDRA 27.0
Systematic Assessment
EG0002 events2 affected3 at risk
EG0012 events2 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Psoriasis
Skin and subcutaneous tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Rash
Skin and subcutaneous tissue disorders
MedDRA 27.0
Systematic Assessment
EG0002 events2 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Rash maculo-papular
Skin and subcutaneous tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Skin ulcer
Skin and subcutaneous tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Vitiligo
Skin and subcutaneous tissue disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Embolism
Vascular disorders
MedDRA 27.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected4 at risk
EG003
Flushing
Vascular disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Haematoma
Vascular disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hypertension
Vascular disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Hypotension
Vascular disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Lymphoedema
Vascular disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Vein disorder
Vascular disorders
MedDRA 27.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected4 at risk
EG003
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0015
OG0024
OG0034
OG0044
OG00519
Title
Denominators
Categories
AEs (Any grade)
Title
Measurements
OG0003
OG0015
OG0024
OG0034
OG0043
OG00518
Grade 1 AE
Title
Measurements
OG0000
OG0013
OG0021
OG003
Grade 2 AE
Title
Measurements
OG0002
OG0011
OG0022
OG003
Grade 3 AE
Title
Measurements
OG0001
OG0011
OG0021
OG003
Grade 4 AE
Title
Measurements
OG0000
OG0010
OG0020
OG003
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to standard therapy received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve esophageal squamous cell carcinoma (ESCC) received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG00038
OG00125
OG00215
OG00315
Title
Denominators
Categories
Title
Measurements
OG0007.9± 2.19(2.19 to 19.16)
OG0010± 0.00(0.00 to 11.29)
OG0020± 0.00(0.00 to 18.10)
OG00320.0± 5.68(5.68 to 43.98)
OG001
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to standard therapy received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve esophageal squamous cell carcinoma (ESCC) received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG00038
OG00125
OG00215
OG00315
Title
Denominators
Categories
Title
Measurements
OG00036.8± 23.83(23.83 to 51.47)
OG00136.0± 20.24(20.24 to 54.39)
OG0020± 0.00(0.00 to 18.10)
OG00360.0± 35.96(35.96 to 80.91)
OG001
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to standard therapy received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve esophageal squamous cell carcinoma (ESCC) received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0010
OG0020
OG0033
Title
Denominators
Categories
Title
Measurements
OG00017.7(3.9 to NA)The upper limit of the 90% confidence interval (CI) was not estimable due to insufficient number of participants with events.
OG00310.6(3.9 to NA)The upper limit of the 90% CI was not estimable due to insufficient number of participants with events.
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to standard therapy received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve esophageal squamous cell carcinoma (ESCC) received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG00038
OG00125
OG00215
OG00315
Title
Denominators
Categories
Title
Measurements
OG0001.8± 1.7(1.7 to 2.0)
OG0011.7± 1.6(1.6 to 1.9)
OG0021.7± 1.6(1.6 to 1.8)
OG0033.6± 1.5(1.5 to 5.7)
OG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG006
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG007
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG008
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to standard therapy received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG009
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve esophageal squamous cell carcinoma (ESCC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0015
OG0024
OG0033
OG0043
OG00517
OG00637
OG00725
OG00814
OG00916
Title
Denominators
Categories
Title
Measurements
OG0003
OG0012
OG0020
OG0030
OG0041
OG0053
OG0065
OG0077
OG0081
OG0096
OG002
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to standard therapy received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve esophageal squamous cell carcinoma (ESCC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG00037
OG00126
OG00215
OG0032
Title
Denominators
Categories
CD3+CD8+: Cycle 1 Day 1
ParticipantsOG00032
ParticipantsOG00124
ParticipantsOG00215
ParticipantsOG0032
Title
Measurements
OG000350.63± 186.81
OG001293.25± 137.62
OG002252.60± 224.48
OG003
CD3+CD8+: Cycle 1 Day 2
ParticipantsOG00036
ParticipantsOG00125
ParticipantsOG00215
ParticipantsOG0032
CD3+CD8+: Cycle 1 Day 8
ParticipantsOG00032
ParticipantsOG00122
ParticipantsOG00215
ParticipantsOG0031
CD3+CD8+: Cycle 2 Day 1
ParticipantsOG00035
ParticipantsOG00123
ParticipantsOG00215
ParticipantsOG0032
CD3+CD8+: Cycle 3 Day 1
ParticipantsOG00032
ParticipantsOG00117
ParticipantsOG00211
ParticipantsOG0031
CD3+CD8+: Cycle 5 Day 1
ParticipantsOG00017
ParticipantsOG0018
ParticipantsOG0024
ParticipantsOG0030
CD3+CD8+: Cycle 5 Day 2
ParticipantsOG00017
ParticipantsOG0017
ParticipantsOG0024
ParticipantsOG0030
CD3+CD8+: Cycle 5 Day 8
ParticipantsOG00015
ParticipantsOG0017
ParticipantsOG0023
ParticipantsOG0030
CD3+CD8+: Cycle 9 Day 1
ParticipantsOG00011
ParticipantsOG0010
ParticipantsOG0021
ParticipantsOG0030
CD3+CD8+: SFU
ParticipantsOG0008
ParticipantsOG0012
ParticipantsOG0022
ParticipantsOG0030
CD3+CD8+: Study Completion
ParticipantsOG00020
ParticipantsOG00112
ParticipantsOG0025
ParticipantsOG0030
CD3+CD8+Ki67+: Cycle 1 Day 1
ParticipantsOG00031
ParticipantsOG00123
ParticipantsOG00214
ParticipantsOG0032
CD3+CD8+Ki67+: Cycle 1 Day 2
ParticipantsOG00036
ParticipantsOG00123
ParticipantsOG00214
ParticipantsOG0032
CD3+CD8+Ki67+: Cycle 1 Day 8
ParticipantsOG00032
ParticipantsOG00122
ParticipantsOG00214
ParticipantsOG0031
CD3+CD8+Ki67+: Cycle 2 Day 1
ParticipantsOG00033
ParticipantsOG00123
ParticipantsOG00215
ParticipantsOG0032
CD3+CD8+Ki67+: Cycle 3 Day 1
ParticipantsOG00031
ParticipantsOG00117
ParticipantsOG00211
ParticipantsOG0031
CD3+CD8+Ki67+: Cycle 5 Day 1
ParticipantsOG00015
ParticipantsOG0018
ParticipantsOG0023
ParticipantsOG0030
CD3+CD8+Ki67+: Cycle 5 Day 2
ParticipantsOG00016
ParticipantsOG0016
ParticipantsOG0024
ParticipantsOG0030
CD3+CD8+Ki67+: Cycle 5 Day 8
ParticipantsOG00015
ParticipantsOG0017
ParticipantsOG0023
ParticipantsOG0030
CD3+CD8+Ki67+: Cycle 9 Day 1
ParticipantsOG00011
ParticipantsOG0010
ParticipantsOG0021
ParticipantsOG0030
CD3+CD8+Ki67+: SFU
ParticipantsOG0008
ParticipantsOG0012
ParticipantsOG0022
ParticipantsOG0030
CD3+CD8+Ki67+: Study Completion
ParticipantsOG00019
ParticipantsOG00112
ParticipantsOG0025
ParticipantsOG0030
OG002
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve SCLC with prior failure of, progression on, or intolerance to standard therapy received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve ESCC received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days)
Units
Counts
Participants
OG00025
OG00119
OG0025
OG0037
Title
Denominators
Categories
Archival Metastasis Samples
ParticipantsOG0007
ParticipantsOG0011
ParticipantsOG0020
ParticipantsOG0030
Title
Measurements
OG000215.16± 319.52
OG00129.51± NASince only 1 participant was analyzed, the SD could not be calculated.
Archival Primary Samples
ParticipantsOG0002
ParticipantsOG0015
ParticipantsOG0020
ParticipantsOG0033
Fresh Sample 1
ParticipantsOG00025
ParticipantsOG00119
ParticipantsOG0025
ParticipantsOG0037
Fresh Sample 2
ParticipantsOG00019
ParticipantsOG0018
ParticipantsOG0021
ParticipantsOG0033
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG006
Part A: Lomvastomig 2100 mg (Extension Cohort 1)
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days). This cohort was initiated after the safety assessment of Cohort "Part A: Lomvastomig 2100 mg".
OG007
Part A: Lomvastomig 2100 mg (Extension Cohort 2)
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days). This cohort was initiated after the safety assessment of Cohort "Part A: Lomvastomig 2100 mg (Extension Cohort 1)".
OG008
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG009
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG010
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to standard therapy received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG011
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve esophageal squamous cell carcinoma (ESCC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0015
OG0024
OG0034
OG0044
OG0054
OG0064
OG00711
OG00838
OG00925
OG01015
OG01116
Title
Denominators
Categories
Cycle 1
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0024
ParticipantsOG0034
ParticipantsOG0044
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG00711
ParticipantsOG00838
ParticipantsOG00925
ParticipantsOG01015
ParticipantsOG01116
Title
Measurements
OG0000.09(0.09 to 0.17)
OG0010.09(0.09 to 1)
OG0020.125(0.09 to 0.17)
OG003
Cycle 5
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0032
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG006
Part A: Lomvastomig 2100 mg (Extension Cohort 1)
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days). This cohort was initiated after the safety assessment of Cohort "Part A: Lomvastomig 2100 mg".
OG007
Part A: Lomvastomig 2100 mg (Extension Cohort 2)
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days). This cohort was initiated after the safety assessment of Cohort "Part A: Lomvastomig 2100 mg (Extension Cohort 1)".
OG008
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG009
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG010
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to standard therapy received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG011
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve esophageal squamous cell carcinoma (ESCC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0015
OG0024
OG0034
OG0044
OG0054
OG0064
OG00711
OG00838
OG00925
OG01015
OG01116
Title
Denominators
Categories
Cycle 1
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0024
ParticipantsOG0034
ParticipantsOG0044
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG00711
ParticipantsOG00838
ParticipantsOG00925
ParticipantsOG01015
ParticipantsOG01116
Title
Measurements
OG00021.5± 40.0
OG00161.7± 25.2
OG002148± 18.5
OG003
Cycle 5
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0032
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG006
Part A: Lomvastomig 2100 mg (Extension Cohort 1)
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days). This cohort was initiated after the safety assessment of Cohort "Part A: Lomvastomig 2100 mg".
OG007
Part A: Lomvastomig 2100 mg (Extension Cohort 2)
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days). This cohort was initiated after the safety assessment of Cohort "Part A: Lomvastomig 2100 mg (Extension Cohort 1)".
OG008
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG009
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG010
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to standard therapy received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG011
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve esophageal squamous cell carcinoma (ESCC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0015
OG0024
OG0034
OG0044
OG0054
OG0064
OG00711
OG00838
OG00925
OG01015
OG01116
Title
Denominators
Categories
Cycle 1
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0024
ParticipantsOG0034
ParticipantsOG0044
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG00711
ParticipantsOG00838
ParticipantsOG00925
ParticipantsOG01015
ParticipantsOG01116
Title
Measurements
OG0000.307± 40.0
OG0010.294± 25.3
OG0020.24± 18.5
OG003
Cycle 5
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0032
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG006
Part A: Lomvastomig 2100 mg (Extension Cohort 1)
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days). This cohort was initiated after the safety assessment of Cohort "Part A: Lomvastomig 2100 mg"
OG007
Part A: Lomvastomig 2100 mg (Extension Cohort 2)
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days). This cohort was initiated after the safety assessment of Cohort "Part A: Lomvastomig 2100 mg (Extension Cohort 1)".
OG008
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG009
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG010
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to standard therapy received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG011
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve esophageal squamous cell carcinoma (ESCC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0015
OG0024
OG0034
OG0044
OG0054
OG0064
OG00711
OG00838
OG00925
OG01015
OG01116
Title
Denominators
Categories
Cycle 1
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0024
ParticipantsOG0034
ParticipantsOG0044
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG00711
ParticipantsOG00838
ParticipantsOG00925
ParticipantsOG01015
ParticipantsOG01116
Title
Measurements
OG00014(13.9 to 14)
OG00114(13.9 to 14)
OG00214(13.9 to 14.1)
OG003
Cycle 5
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0032
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG006
Part A: Lomvastomig 2100 mg (Extension Cohort 1)
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days). This cohort was initiated after the safety assessment of Cohort "Part A: Lomvastomig 2100 mg".
OG007
Part A: Lomvastomig 2100 mg (Extension Cohort 2)
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days). This cohort was initiated after the safety assessment of Cohort "Part A: Lomvastomig 2100 mg (Extension Cohort 1)".
OG008
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG009
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG010
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to standard therapy received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG011
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve esophageal squamous cell carcinoma (ESCC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0015
OG0024
OG0034
OG0044
OG0054
OG0064
OG00711
OG00838
OG00925
OG01015
OG01116
Title
Denominators
Categories
Cycle 1
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0024
ParticipantsOG0034
ParticipantsOG0044
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG00711
ParticipantsOG00838
ParticipantsOG00925
ParticipantsOG01015
ParticipantsOG01116
Title
Measurements
OG0005.52± 23.6
OG00121.4± 9.2
OG00240.4± 43.2
OG003
Cycle 5
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0032
OG001
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG006
Part A: Lomvastomig 2100 mg (Extension Cohort 1)
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days). This cohort was initiated after the safety assessment of Cohort "Part A: Lomvastomig 2100 mg".
OG007
Part A: Lomvastomig 2100 mg (Extension Cohort 2)
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days). This cohort was initiated after the safety assessment of Cohort "Part A: Lomvastomig 2100 mg (Extension Cohort 1)".
OG008
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG009
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG010
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to standard therapy received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG011
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve esophageal squamous cell carcinoma (ESCC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0015
OG0024
OG0034
OG0044
OG0054
OG0064
OG00711
OG00838
OG00925
OG01015
OG01116
Title
Denominators
Categories
Cycle 1
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0024
ParticipantsOG0034
ParticipantsOG0044
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG00711
ParticipantsOG00838
ParticipantsOG00925
ParticipantsOG01015
ParticipantsOG01116
Title
Measurements
OG000140± 37.8
OG001426± 16.0
OG002927± 28.8
OG003
Cycle 5
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0032
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG006
Part A: Lomvastomig 2100 mg (Extension Cohort 1)
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days). This cohort was initiated after the safety assessment of Cohort "Part A: Lomvastomig 2100 mg".
OG007
Part A: Lomvastomig 2100 mg (Extension Cohort 2)
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days). This cohort was initiated after the safety assessment of Cohort "Part A: Lomvastomig 2100 mg (Extension Cohort 1)".
OG008
Part B1: Metastatic Melanoma Expansion Cohort
Participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG009
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG010
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to standard therapy received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG011
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve esophageal squamous cell carcinoma (ESCC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0015
OG0024
OG0034
OG0044
OG0054
OG0064
OG00711
OG00838
OG00925
OG01015
OG01116
Title
Denominators
Categories
Cycle 1
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0024
ParticipantsOG0034
ParticipantsOG0044
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG00711
ParticipantsOG00838
ParticipantsOG00925
ParticipantsOG01015
ParticipantsOG01116
Title
Measurements
OG000140± 37.8
OG001427± 15.9
OG002932± 29.0
OG003
Cycle 5
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0032
OG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0015
OG0024
OG0034
OG0044
OG00518
Title
Denominators
Categories
CD3+: Predose on Cycle 1 Day 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0034
ParticipantsOG0040
ParticipantsOG00518
Title
Measurements
OG00041.80± 37.87
OG00136.23± 26.52
OG00234.77± 7.79
OG003
CD3+: EOI on Cycle 1 Day 1
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0024
ParticipantsOG0034
CD3+: Postdose on Cycle 1 Day 8
ParticipantsOG0003
ParticipantsOG0014
ParticipantsOG0024
ParticipantsOG0034
CD3+: Predose on Cycle 2 Day 1
ParticipantsOG0003
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0033
CD3+: Predose on Cycle 3 Day 1
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0021
ParticipantsOG0032
CD3+:Predose on Cycle 5 Day 1
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0021
ParticipantsOG0031
CD3+: EOI on Cycle 5 Day 1
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0021
ParticipantsOG0031
CD3+: Postdose on Cycle 5 Day 8
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0020
ParticipantsOG0032
CD3+: Predose on Cycle 9 Day 1
ParticipantsOG0001
ParticipantsOG0012
ParticipantsOG0020
ParticipantsOG0031
CD3+: SFU
ParticipantsOG0002
ParticipantsOG0012
ParticipantsOG0020
ParticipantsOG0031
CD3+: Study Completion
ParticipantsOG0002
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0032
CD4+: Predose on Cycle 1 Day 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
CD4+: EOI on Cycle 1 Day 1
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0024
ParticipantsOG0034
CD4+: Postdose on Cycle 1 Day 8
ParticipantsOG0002
ParticipantsOG0014
ParticipantsOG0024
ParticipantsOG0034
CD4+: Predose on Cycle 2 Day 1
ParticipantsOG0003
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0033
CD4+: Predose on Cycle 3 Day 1
ParticipantsOG0002
ParticipantsOG0015
ParticipantsOG0021
ParticipantsOG0032
CD4+: Predose on Cycle 5 Day 1
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0021
ParticipantsOG0031
CD4+: EOI on Cycle 5 Day 1
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0021
ParticipantsOG0031
CD4+: Postdose on Cycle 5 Day 1
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0020
ParticipantsOG0032
CD4+: Predose on Cycle 9 Day 1
ParticipantsOG0001
ParticipantsOG0012
ParticipantsOG0020
ParticipantsOG0031
CD4+: SFU
ParticipantsOG0001
ParticipantsOG0012
ParticipantsOG0020
ParticipantsOG0031
CD4+: Study Completion
ParticipantsOG0002
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0032
CD56+/16+:Predose on Cycle 1 Day 1
ParticipantsOG0003
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0033
CD56+/16+:EOI on Cycle 1 Day 1
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0024
ParticipantsOG0034
CD56+/16+:Postdose on Cycle 1 Day 8
ParticipantsOG0003
ParticipantsOG0014
ParticipantsOG0024
ParticipantsOG0033
CD56+/16+:Predose on Cycle 2 Day 1
ParticipantsOG0003
ParticipantsOG0014
ParticipantsOG0024
ParticipantsOG0033
CD56+/16+:Predose on Cycle 3 Day 1
ParticipantsOG0002
ParticipantsOG0015
ParticipantsOG0022
ParticipantsOG0032
CD56+/16+:Predose on Cycle 5 Day 1
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0031
CD56+/16+:EOI on Cycle 5 Day 1
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0031
CD56+/16+:Postdose on Cycle 5 Day 8
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0032
CD56+/16+:Predose on Cycle 9 Day 1
ParticipantsOG0001
ParticipantsOG0012
ParticipantsOG0020
ParticipantsOG0031
CD56+/16+: SFU
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
CD56+/16+: Study Completion
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
CD8+: Predose on Cycle 1 Day 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
CD8+: EOI on Cycle 1 Day 1
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0024
ParticipantsOG0034
CD8+: Postdose on Cycle 1 Day 8
ParticipantsOG0003
ParticipantsOG0014
ParticipantsOG0024
ParticipantsOG0034
CD8+: Predose on Cycle 2 Day 1
ParticipantsOG0003
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0033
CD8+: Predose on Cycle 3 Day 1
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0021
ParticipantsOG0032
CD8+: Predose on Cycle 5 Day 1
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0021
ParticipantsOG0031
CD8+: EOI on Cycle 5 Day 1
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0021
ParticipantsOG0031
CD8+: Postdose on Cycle 5 Day 8
ParticipantsOG0001
ParticipantsOG0013
ParticipantsOG0020
ParticipantsOG0032
CD8+: Predose on Cycle 9 Day 1
ParticipantsOG0001
ParticipantsOG0012
ParticipantsOG0020
ParticipantsOG0031
CD8+: SFU
ParticipantsOG0002
ParticipantsOG0012
ParticipantsOG0020
ParticipantsOG0031
CD8+: Study Completion
ParticipantsOG0002
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0032
OG001
Part B2: NSCLC Expansion Cohort 1
Participants with CPI and platinum experienced second- or third-line programmed death-ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part B4: SCLC Expansion Cohort
Participants with CPI-naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to standard therapy received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part B5: ESCC Expansion Cohort
Participants with CPI-naïve esophageal squamous cell carcinoma (ESCC) received 2100 mg, lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG00038
OG00126
OG00215
OG00316
Title
Denominators
Categories
AEs (Any Grade)
Title
Measurements
OG00034
OG00125
OG00215
OG00316
Grade 1 AE
Title
Measurements
OG0007
OG0015
OG0022
OG003
Grade 2 AE
Title
Measurements
OG00015
OG00110
OG0025
OG003
Grade 3 AE
Title
Measurements
OG00011
OG0019
OG0028
OG003
Grade 4 AE
Title
Measurements
OG0001
OG0010
OG0020
OG003
Grade 5 AE
Title
Measurements
OG0000
OG0011
OG0020
OG003
OG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0015
OG0024
OG0034
OG0044
OG00519
Title
Denominators
Categories
Title
Measurements
OG0000± 0.00(0.00 to 63.16)
OG0010± 0.00(0.00 to 45.07)
OG0020± 0.00(0.00 to 52.71)
OG0030± 0.00(0.00 to 52.71)
OG0040± 0.00(0.00 to 52.71)
OG00521.1± 7.53(7.53 to 41.91)
OG001
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0015
OG0024
OG0034
OG0044
OG00519
Title
Denominators
Categories
Title
Measurements
OG00033.3(1.70 to 86.46)
OG00140.0(7.64 to 81.07)
OG0020(0.00 to 52.71)
OG00350.0(9.76 to 90.24)
OG00425.0(1.27 to 75.14)
OG00542.1(22.97 to 63.19)
OG001
Part A: Lomvastomig 210 mg
Participants received 210 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter or until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0000
OG0010
OG0020
OG0030
OG0040
OG0054
Title
Denominators
Categories
Title
Measurements
OG00513.8(5.6 to NA)The upper limit of the 90% CI was not estimable due to insufficient number of participants with events.
OG002
Part A: Lomvastomig 615 mg
Participants received 615 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG003
Part A: Lomvastomig 1200 mg
Participants received 1200 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG004
Part A: Lomvastomig 1800 mg
Participants received 1800 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
OG005
Part A: Lomvastomig 2100 mg
Participants received 2100 mg of lomvastomig, as an IV infusion on Cycle 1 Day 1 and Q2W thereafter until disease progression, unacceptable toxicities, or withdrawal of consent, whichever occurred first (Cycle length = 14 days).
Units
Counts
Participants
OG0003
OG0015
OG0024
OG0034
OG0044
OG00519
Title
Denominators
Categories
Title
Measurements
OG0001.8(1.7 to NA)The upper limit of the 90% CI was not estimable due to insufficient number of participants with events.
OG0012.0(1.9 to 5.4)
OG0021.6(1.0 to NA)The upper limit of the 90% CI was not estimable due to insufficient number of participants with events.
OG003NA(0.7 to NA)The median and upper limit of the 90% CI was not estimable due to insufficient number of participants with events.
OG0041.8(0.6 to NA)The upper limit of the 90% CI was not estimable due to insufficient number of participants with events.
OG0051.9(1.7 to 3.5)
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0092 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0062 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0056 events3 affected19 at risk
EG0060 events0 affected38 at risk
EG0072 events2 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0052 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0054 events3 affected19 at risk
EG0061 events1 affected38 at risk
EG0072 events2 affected26 at risk
EG0080 events0 affected15 at risk
EG0092 events2 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0062 events2 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0092 events2 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0092 events2 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0053 events3 affected19 at risk
EG0067 events5 affected38 at risk
EG0072 events2 affected26 at risk
EG0084 events4 affected15 at risk
EG0092 events2 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0063 events3 affected38 at risk
EG0071 events1 affected26 at risk
EG0082 events2 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0053 events2 affected19 at risk
EG0068 events7 affected38 at risk
EG0076 events6 affected26 at risk
EG0084 events4 affected15 at risk
EG0095 events5 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0059 events3 affected19 at risk
EG0066 events6 affected38 at risk
EG0071 events1 affected26 at risk
EG0082 events2 affected15 at risk
EG0098 events6 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0052 events2 affected19 at risk
EG0062 events2 affected38 at risk
EG0072 events2 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0062 events2 affected38 at risk
EG0071 events1 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0062 events2 affected38 at risk
EG0072 events2 affected26 at risk
EG0080 events0 affected15 at risk
EG0094 events3 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0042 events1 affected4 at risk
EG0054 events4 affected19 at risk
EG00610 events8 affected38 at risk
EG0076 events3 affected26 at risk
EG0082 events2 affected15 at risk
EG0095 events5 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0042 events1 affected4 at risk
EG0052 events2 affected19 at risk
EG00615 events9 affected38 at risk
EG0073 events3 affected26 at risk
EG0081 events1 affected15 at risk
EG0094 events2 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0057 events5 affected19 at risk
EG00620 events16 affected38 at risk
EG0078 events8 affected26 at risk
EG0085 events5 affected15 at risk
EG0092 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0082 events1 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0053 events2 affected19 at risk
EG0060 events0 affected38 at risk
EG0073 events2 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0052 events1 affected19 at risk
EG0068 events6 affected38 at risk
EG0076 events5 affected26 at risk
EG0084 events4 affected15 at risk
EG0098 events7 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0052 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0067 events6 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0052 events2 affected19 at risk
EG0062 events2 affected38 at risk
EG0073 events2 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0055 events3 affected19 at risk
EG0067 events4 affected38 at risk
EG0076 events6 affected26 at risk
EG0080 events0 affected15 at risk
EG0092 events2 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0092 events2 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0092 events2 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0050 events0 affected19 at risk
EG0062 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0076 events3 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0062 events2 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0042 events1 affected4 at risk
EG0052 events2 affected19 at risk
EG0062 events2 affected38 at risk
EG0074 events4 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0052 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0081 events1 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0052 events2 affected19 at risk
EG0063 events3 affected38 at risk
EG0072 events2 affected26 at risk
EG0083 events3 affected15 at risk
EG0092 events2 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0054 events4 affected19 at risk
EG0062 events2 affected38 at risk
EG0072 events2 affected26 at risk
EG0083 events3 affected15 at risk
EG0093 events3 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0063 events3 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0052 events2 affected19 at risk
EG0061 events1 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0056 events2 affected19 at risk
EG0062 events2 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0063 events2 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0061 events1 affected38 at risk
EG0072 events2 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0053 events3 affected19 at risk
EG0063 events3 affected38 at risk
EG0073 events3 affected26 at risk
EG0081 events1 affected15 at risk
EG0092 events2 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
2 events
2 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0064 events4 affected38 at risk
EG0072 events2 affected26 at risk
EG0080 events0 affected15 at risk
EG0095 events5 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0055 events2 affected19 at risk
EG00610 events9 affected38 at risk
EG0074 events4 affected26 at risk
EG0084 events4 affected15 at risk
EG0093 events3 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0093 events3 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0052 events2 affected19 at risk
EG0061 events1 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0072 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0052 events2 affected19 at risk
EG0063 events3 affected38 at risk
EG0071 events1 affected26 at risk
EG0081 events1 affected15 at risk
EG0092 events2 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0053 events2 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0081 events1 affected15 at risk
EG0095 events4 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0062 events2 affected38 at risk
EG0072 events2 affected26 at risk
EG0081 events1 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0095 events4 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
1 events
1 affected
4 at risk
EG0041 events1 affected4 at risk
EG0052 events2 affected19 at risk
EG0068 events7 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0094 events2 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0054 events3 affected19 at risk
EG0062 events2 affected38 at risk
EG0074 events4 affected26 at risk
EG0084 events4 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0092 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
2 events
2 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0062 events2 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0062 events2 affected38 at risk
EG0072 events2 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0062 events2 affected38 at risk
EG0071 events1 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0093 events3 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0062 events2 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0063 events3 affected38 at risk
EG0073 events3 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0050 events0 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0055 events5 affected19 at risk
EG0064 events4 affected38 at risk
EG0071 events1 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0062 events2 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0064 events3 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0062 events2 affected38 at risk
EG0073 events3 affected26 at risk
EG0080 events0 affected15 at risk
EG0092 events2 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0064 events4 affected38 at risk
EG0071 events1 affected26 at risk
EG0082 events2 affected15 at risk
EG0094 events3 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0062 events2 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
1 events
1 affected
4 at risk
EG0041 events1 affected4 at risk
EG0054 events4 affected19 at risk
EG0062 events2 affected38 at risk
EG0075 events5 affected26 at risk
EG0082 events2 affected15 at risk
EG0095 events3 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
2 events
2 affected
4 at risk
EG0041 events1 affected4 at risk
EG0057 events7 affected19 at risk
EG0066 events4 affected38 at risk
EG0076 events6 affected26 at risk
EG0082 events2 affected15 at risk
EG0094 events3 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0074 events3 affected26 at risk
EG0081 events1 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0061 events1 affected38 at risk
EG0073 events3 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0052 events1 affected19 at risk
EG0066 events5 affected38 at risk
EG0071 events1 affected26 at risk
EG0084 events4 affected15 at risk
EG0093 events3 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0061 events1 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0052 events1 affected19 at risk
EG0065 events3 affected38 at risk
EG0073 events3 affected26 at risk
EG0080 events0 affected15 at risk
EG0094 events3 affected16 at risk
0 events
0 affected
4 at risk
EG0041 events1 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0062 events2 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0051 events1 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0042 events2 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0081 events1 affected15 at risk
EG0092 events2 affected16 at risk
1 events
1 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected16 at risk
0 events
0 affected
4 at risk
EG0040 events0 affected4 at risk
EG0050 events0 affected19 at risk
EG0060 events0 affected38 at risk
EG0070 events0 affected26 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected16 at risk
0
OG0040
OG0052
2
OG0041
OG0059
1
OG0042
OG0057
1
OG0040
OG0050
256.00
± 138.59
Title
Measurements
OG000371.61± 219.58
OG001317.28± 175.47
OG002296.20± 519.44
OG003306.50± 111.02
Title
Measurements
OG000364.09± 264.35
OG001342.59± 223.74
OG002292.47± 349.48
OG003329.00± NASince only 1 participant was analyzed, the standard deviation (SD) could not be calculated.
Title
Measurements
OG000378.54± 250.58
OG001298.91± 153.88
OG002245.93± 226.21
OG003257.00± 66.47
Title
Measurements
OG000422.00± 380.62
OG001310.47± 171.87
OG002193.18± 81.24
OG003199.00± NASince only 1 participant was analyzed, the SD could not be calculated.
Title
Measurements
OG000403.88± 270.34
OG001269.00± 106.32
OG002234.00± 72.48
Title
Measurements
OG000445.53± 228.03
OG001285.71± 120.35
OG002260.50± 59.52
Title
Measurements
OG000516.80± 332.31
OG001267.57± 116.42
OG002179.00± 68.02
Title
Measurements
OG000503.91± 425.19
OG002237.00± NASince only 1 participant was analyzed, the SD could not be calculated.
Title
Measurements
OG000429.38± 302.79
OG001453.00± 212.13
OG002201.00± 209.30
Title
Measurements
OG000296.70± 177.13
OG001289.83± 168.98
OG002193.80± 136.60
Title
Measurements
OG00012.45± 8.64
OG00111.83± 8.67
OG0027.36± 5.51
OG0035.50± 2.12
Title
Measurements
OG00013.94± 16.29
OG00113.00± 12.76
OG0027.71± 7.45
OG0038.00± 2.83
Title
Measurements
OG00014.34± 11.67
OG00113.64± 12.62
OG00211.00± 4.88
OG00313.00± NASince only 1 participant was analyzed, the SD could not be calculated.
Title
Measurements
OG00018.12± 22.33
OG00117.52± 23.14
OG00214.87± 6.62
OG0038.50± 0.71
Title
Measurements
OG00016.10± 23.21
OG00113.41± 9.21
OG00213.45± 8.71
OG0038.00± NASince only 1 participant was analyzed, the SD could not be calculated.
Title
Measurements
OG00016.27± 12.27
OG0016.88± 2.42
OG0029.00± 1.73
Title
Measurements
OG00019.63± 26.26
OG0017.83± 4.17
OG0026.75± 2.22
Title
Measurements
OG00015.33± 9.98
OG0017.00± 2.08
OG0026.67± 3.79
Title
Measurements
OG00014.27± 12.58
OG0026.00± NASince only 1 participant was analyzed, the SD could not be calculated.
Title
Measurements
OG00015.63± 12.93
OG00122.50± 14.85
OG0027.50± 7.78
Title
Measurements
OG00010.58± 7.80
OG0019.58± 10.49
OG00214.80± 9.31
Title
Measurements
OG000374.92± 530.17
OG001764.26± 470.25
OG003275.02± 347.75
Title
Measurements
OG0001090.51± 1001.71
OG001765.44± 986.47
OG002221.87± 363.76
OG003510.21± 601.10
Title
Measurements
OG000912.58± 1089.90
OG001790.76± 462.38
OG002288.21± NASince only 1 participant was analyzed, the SD could not be calculated.
OG003322.23± 256.74
0.17
(0.09 to 0.26)
OG0040.17(0.17 to 0.25)
OG0050.09(0.09 to 0.19)
OG0060.175(0.17 to 0.25)
OG0070.18(0.09 to 0.28)
OG0080.17(0.04 to 1.24)
OG0090.1(0.04 to 0.18)
OG0100.17(0.09 to 0.91)
OG0110.17(0.08 to 0.25)
Participants
OG004
2
ParticipantsOG0051
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG00821
ParticipantsOG00911
ParticipantsOG0104
ParticipantsOG0119
Title
Measurements
OG0000.16(0.16 to 0.16)
OG0010.17(0.09 to 0.25)
OG0022.5(1 to 4.01)
OG0033.57(1.12 to 6.02)
OG0040.17(0.17 to 0.17)
OG0050.17(0.17 to 0.17)
OG0060.21(0.09 to 0.22)
OG0070.215(0.09 to 0.23)
OG0080.1(0 to 0.98)
OG0090.1(0.02 to 3.13)
OG0100.11(0.03 to 0.11)
OG0110.1(0.01 to 0.88)
408
± 5.7
OG004530± 20.8
OG005518± 8.8
OG006575± 29.4
OG007740± 14.4
OG008791± 43.3
OG009704± 26.2
OG010726± 16.1
OG011754± 24.5
Participants
OG004
2
ParticipantsOG0051
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG00821
ParticipantsOG00911
ParticipantsOG0104
ParticipantsOG0119
Title
Measurements
OG00020.2± NASince only 1 participant was analyzed, the geometric coefficient of variation could not be calculated.
OG001128± 8.3
OG002116± 116.9
OG003546± 14.8
OG004781± 30.8
OG0051600± NASince only 1 participant was analyzed, the geometric coefficient of variation could not be calculated.
OG0061500± 0.0
OG0071520± 17.5
OG0081420± 32.6
OG0091270± 33.1
OG0101240± 23.0
OG0111280± 25.7
0.34
± 5.7
OG0040.295± 20.9
OG0050.246± 8.8
OG0060.274± 29.4
OG0070.352± 14.3
OG0080.377± 43.2
OG0090.335± 26.2
OG0100.346± 16.1
OG0110.359± 24.4
Participants
OG004
2
ParticipantsOG0051
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG00821
ParticipantsOG00911
ParticipantsOG0104
ParticipantsOG0119
Title
Measurements
OG0000.777± NASince only 1 participant was analyzed, the geometric coefficient of variation could not be calculated.
OG0010.608± 8.4
OG0020.188± 117.0
OG0030.455± 14.8
OG0040.434± 30.8
OG0050.762± NASince only 1 participant was analyzed, the geometric coefficient of variation could not be calculated.
OG0060.714± 0.0
OG0070.725± 17.5
OG0080.675± 32.6
OG0090.607± 33.0
OG0100.592± 22.9
OG0110.609± 25.8
14
(11.8 to 14.2)
OG00414(11 to 14.1)
OG00514(4.06 to 14.1)
OG00614.1(13.9 to 14.2)
OG00714(6.97 to 14.3)
OG00814(6.07 to 16)
OG00914(10.1 to 42)
OG01014(13.9 to 22.1)
OG01114(10.9 to 28)
Participants
OG004
2
ParticipantsOG0051
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG00821
ParticipantsOG00911
ParticipantsOG0104
ParticipantsOG0119
Title
Measurements
OG00016.9(16.9 to 16.9)
OG00114(14 to 14)
OG00214.1(14 to 14.1)
OG00314.1(14 to 14.1)
OG00415(14.1 to 16)
OG00514(14 to 14)
OG00614(14 to 28)
OG00714.5(13.9 to 16)
OG00814(13.8 to 20.2)
OG00914(13.9 to 22)
OG01014.5(12.9 to 17)
OG01114.2(13.9 to 21)
116
± 17.0
OG004147± 39.1
OG005157± 43.2
OG006157± 29.4
OG007245± 29.3
OG008217± 38.2
OG009184± 54.1
OG010194± 24.8
OG011216± 46.1
Participants
OG004
2
ParticipantsOG0051
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG00821
ParticipantsOG00911
ParticipantsOG0104
ParticipantsOG0119
Title
Measurements
OG0002.16± NASince only 1 participant was analyzed, the geometric coefficient of variation could not be calculated.
OG00162.2± 14.5
OG00259.7± 37.4
OG003267± 8.8
OG004415± 24.6
OG005661± NASince only 1 participant was analyzed, the geometric coefficient of variation could not be calculated.
OG006549± 22.0
OG007678± 32.7
OG008520± 49.6
OG009495± 39.2
OG010470± 59.0
OG011533± 44.3
2540
± 22.1
OG0043040± 31.6
OG0052700± 52.0
OG0063700± 26.8
OG0074880± 30.0
OG0084700± 27.9
OG0094600± 27.3
OG0104720± 25.7
OG0115200± 24.4
Participants
OG004
2
ParticipantsOG0051
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG00821
ParticipantsOG00911
ParticipantsOG0104
ParticipantsOG0119
Title
Measurements
OG000114± NASince only 1 participant was analyzed, the geometric coefficient of variation could not be calculated.
OG0011200± 8.0
OG0021120± 73.6
OG0035470± 17.3
OG0046620± 13.6
OG00512200± NASince only 1 participant was analyzed, the geometric coefficient of variation could not be calculated.
OG00613800± 28.0
OG00714200± 28.4
OG00811500± 43.5
OG00911700± 38.1
OG0109910± 39.5
OG01111700± 28.7
2600
± 17.4
OG0043120± 26.6
OG0053180± 17.3
OG0063680± 26.9
OG0075060± 20.0
OG0084730± 24.0
OG0094550± 29.6
OG0104590± 20.2
OG0115150± 25.4
Participants
OG004
2
ParticipantsOG0051
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG00821
ParticipantsOG00911
ParticipantsOG0104
ParticipantsOG0119
Title
Measurements
OG000105± NASince only 1 participant was analyzed, the geometric coefficient of variation could not be calculated.
OG0011190± 7.7
OG0021110± 74.2
OG0035440± 17.6
OG0046260± 21.3
OG00512300± NASince only 1 participant was analyzed, the geometric coefficient of variation could not be calculated.
OG00611700± 1.3
OG00713700± 26.4
OG00811200± 41.1
OG00911200± 36.1
OG0109650± 41.5
OG01111100± 33.6
0.28
± 0.55
OG00514.37± 21.43
ParticipantsOG0043
ParticipantsOG00518
Title
Measurements
OG00070.43± 46.32
OG00193.22± 3.03
OG002106.48± 5.25
OG00398.73± 12.28
OG00497.47± 10.11
OG00595.69± 24.36
ParticipantsOG0041
ParticipantsOG00515
Title
Measurements
OG000108.47± 4.50
OG00199.03± 14.31
OG002105.33± 19.23
OG00390.10± 15.62
OG00491.30± NASince only 1 participant was analyzed, SD could not be calculated.
OG005102.53± 20.01
ParticipantsOG0041
ParticipantsOG00513
Title
Measurements
OG000105.13± 9.63
OG00195.53± 4.74
OG00292.80± 15.65
OG00393.17± 4.25
OG004100.00± NASince only 1 participant was analyzed, SD could not be calculated.
OG005100.30± 12.10
ParticipantsOG0041
ParticipantsOG00513
Title
Measurements
OG000100.33± 8.21
OG00190.62± 9.67
OG00252.20± NASince only 1 participant was analyzed, SD could not be calculated.
OG00392.90± 11.46
OG00496.90± NASince only 1 participant was analyzed, SD could not be calculated.
OG005105.48± 25.17
ParticipantsOG0042
ParticipantsOG0056
Title
Measurements
OG00062.10± NASince only 1 participant was analyzed, SD could not be calculated.
OG001100.20± 5.10
OG002124.10± NASince only 1 participant was analyzed, SD could not be calculated..
OG003140.50± NASince only 1 participant was analyzed, SD could not be calculated.
OG00494.90± 8.77
OG00592.72± 48.52
ParticipantsOG0041
ParticipantsOG0057
Title
Measurements
OG00082.60± NASince only 1 participant was analyzed, SD could not be calculated.
OG00195.23± 16.77
OG002128.60± NASince only 1 participant was analyzed, SD could not be calculated.
OG003106.60± NASince only 1 participant was analyzed, SD could not be calculated.
OG00482.20± NASince only 1 participant was analyzed, SD could not be calculated.
OG00595.77± 12.49
ParticipantsOG0042
ParticipantsOG0059
Title
Measurements
OG000206.70± NASince only 1 participant was analyzed, SD could not be calculated.
OG00193.17± 12.72
OG00396.95± 4.31
OG004106.90± 12.30
OG005108.28± 15.34
ParticipantsOG0042
ParticipantsOG0054
Title
Measurements
OG000117.90± NASince only 1 participant was analyzed, SD could not be calculated.
OG00192.45± 6.58
OG003101.20± NASince only 1 participant was analyzed, SD could not be calculated.
OG004101.40± 0.00
OG005113.55± 20.00
Participants
OG004
2
ParticipantsOG0052
Title
Measurements
OG00098.70± 1.84
OG001128.10± 18.38
OG00395.00± NASince only 1 participant was analyzed, SD could not be calculated.
OG00490.25± 2.05
OG00598.35± 2.33
ParticipantsOG0042
ParticipantsOG0058
Title
Measurements
OG00086.35± 7.71
OG00188.93± 6.90
OG00294.75± 21.57
OG00398.95± 9.69
OG004100.50± 0.71
OG00596.73± 9.11
ParticipantsOG0040
ParticipantsOG00515
Title
Measurements
OG00039.93± 29.46
OG00137.77± 32.40
OG00230.07± 1.95
OG0035.70± 7.96
OG00516.37± 20.93
ParticipantsOG0043
ParticipantsOG00518
Title
Measurements
OG00068.60± 47.94
OG00192.28± 5.74
OG002107.58± 3.57
OG00399.80± 11.72
OG004102.67± 12.71
OG00596.63± 25.26
ParticipantsOG0041
ParticipantsOG00515
Title
Measurements
OG00097.65± 16.48
OG001101.40± 16.85
OG002106.53± 21.55
OG00392.18± 13.53
OG00488.40± NASince only 1 participant was analyzed, SD could not be calculated.
OG005103.77± 28.34
ParticipantsOG0041
ParticipantsOG00513
Title
Measurements
OG00098.77± 16.42
OG00194.28± 5.71
OG00297.23± 10.71
OG00391.33± 9.38
OG004102.00± NASince only 1 participant was analyzed, SD could not be calculated.
OG005100.77± 12.11
ParticipantsOG0041
ParticipantsOG00513
Title
Measurements
OG00094.40± 3.82
OG00193.38± 7.51
OG00260.60± NASince only 1 participant was analyzed, SD could not be calculated.
OG00390.00± 9.48
OG004100.00± NASince only 1 participant was analyzed, SD could not be calculated.
OG00598.44± 33.59
ParticipantsOG0042
ParticipantsOG0055
Title
Measurements
OG00068.60± NASince only 1 participant was analyzed, SD could not be calculated.
OG00196.27± 7.48
OG002144.70± NASince only 1 participant was analyzed, SD could not be calculated.
OG003165.50± NASince only 1 participant was analyzed, SD could not be calculated.
OG00495.65± 6.15
OG005112.00± 17.78
ParticipantsOG0041
ParticipantsOG0057
Title
Measurements
OG000103.10± NASince only 1 participant was analyzed, SD could not be calculated.
OG00191.80± 18.83
OG002130.30± NASince only 1 participant was analyzed, SD could not be calculated.
OG003114.60± NASince only 1 participant was analyzed, SD could not be calculated.
OG00479.10± NASince only 1 participant was analyzed, SD could not be calculated.
OG00594.86± 20.02
ParticipantsOG0042
ParticipantsOG0058
Title
Measurements
OG000146.70± NASince only 1 participant was analyzed, SD could not be calculated.
OG00195.60± 11.36
OG00397.60± 8.77
OG004108.10± 14.42
OG005102.90± 16.18
ParticipantsOG0042
ParticipantsOG0054
Title
Measurements
OG000108.20± NASince only 1 participant was analyzed, SD could not be calculated.
OG00193.55± 15.06
OG003105.10± NASince only 1 participant was analyzed, SD could not be calculated.
OG00499.15± 5.16
OG005109.45± 12.18
Participants
OG004
2
ParticipantsOG0052
Title
Measurements
OG00088.00± NASince only 1 participant was analyzed, SD could not be calculated.
OG001129.45± 31.47
OG00394.60± NASince only 1 participant was analyzed, SD could not be calculated.
OG00492.15± 2.19
OG00598.30± 5.23
ParticipantsOG0042
ParticipantsOG0058
Title
Measurements
OG00087.05± 8.70
OG00195.07± 4.60
OG00298.40± 24.04
OG00397.65± 7.99
OG004100.95± 1.34
OG00597.98± 10.69
ParticipantsOG0042
ParticipantsOG00518
Title
Measurements
OG00057.53± 49.85
OG00188.43± 37.59
OG00288.87± 11.20
OG00337.73± 65.36
OG00473.55± 27.93
OG00588.31± 43.57
ParticipantsOG0043
ParticipantsOG00518
Title
Measurements
OG00086.80± 29.86
OG001100.32± 22.37
OG002107.25± 10.70
OG00390.58± 73.61
OG004117.73± 38.13
OG005103.07± 27.26
ParticipantsOG0042
ParticipantsOG00517
Title
Measurements
OG00098.43± 56.80
OG001123.60± 49.67
OG00290.18± 9.67
OG00367.53± 17.54
OG004101.90± 39.74
OG005106.75± 64.75
ParticipantsOG0042
ParticipantsOG00516
Title
Measurements
OG000100.00± 0.00
OG00189.10± 3.99
OG00247.83± 36.63
OG00334.83± 30.25
OG004112.15± 35.85
OG005101.78± 20.05
ParticipantsOG0043
ParticipantsOG00514
Title
Measurements
OG00020.00± 28.28
OG00160.76± 36.97
OG00242.40± 59.96
OG00355.35± 31.18
OG00471.83± 18.61
OG005115.75± 57.23
ParticipantsOG0042
ParticipantsOG0058
Title
Measurements
OG000100.00± NASince only 1 participant was analyzed, SD could not be calculated.
OG00182.10± 21.67
OG00250.80± 5.23
OG00325.00± NASince only 1 participant was analyzed, SD could not be calculated.
OG00490.35± 2.05
OG005107.54± 26.49
ParticipantsOG0041
ParticipantsOG0059
Title
Measurements
OG00073.90± NASince only 1 participant was analyzed, SD could not be calculated.
OG00173.33± 64.07
OG00232.15± 25.24
OG00375.00± NASince only 1 participant was analyzed, SD could not be calculated.
OG00491.00± NASince only 1 participant was analyzed, SD could not be calculated.
OG005100.64± 11.65
ParticipantsOG0042
ParticipantsOG0058
Title
Measurements
OG0003000.00± NASince only 1 participant was analyzed, SD could not be calculated.
OG001108.97± 15.53
OG0020.00± 0.00
OG00383.35± 23.55
OG004100.50± 3.96
OG005107.59± 31.13
ParticipantsOG0042
ParticipantsOG0055
Title
Measurements
OG000194.10± NASince only 1 participant was analyzed, SD could not be calculated.
OG00125.00± 35.36
OG003105.60± NASince only 1 participant was analyzed, SD could not be calculated.
OG00489.00± 4.67
OG00598.86± 18.06
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0040
ParticipantsOG00515
Title
Measurements
OG00036.37± 40.21
OG00136.23± 23.99
OG00253.37± 18.41
OG0030.00± 0.00
OG00517.60± 25.08
ParticipantsOG0043
ParticipantsOG00517
Title
Measurements
OG00074.37± 44.30
OG00195.60± 4.75
OG002106.88± 11.27
OG00397.18± 12.62
OG00494.80± 19.83
OG00599.85± 25.09
ParticipantsOG0041
ParticipantsOG00515
Title
Measurements
OG000109.03± 9.42
OG00197.48± 10.55
OG002107.10± 19.15
OG00391.88± 19.21
OG004100.00± NASince only 1 participant was analyzed, SD could not be calculated.
OG005105.34± 23.71
ParticipantsOG0041
ParticipantsOG00513
Title
Measurements
OG000113.70± 2.36
OG00195.95± 3.72
OG00295.13± 27.80
OG00396.63± 5.83
OG00495.00± NASince only 1 participant was analyzed, SD could not be calculated.
OG00598.85± 16.69
ParticipantsOG0041
ParticipantsOG00512
Title
Measurements
OG000109.13± 22.69
OG00188.66± 11.84
OG00258.30± NASince only 1 participant was analyzed, SD could not be calculated.
OG00394.50± 8.91
OG004100.00± NASince only 1 participant was analyzed, SD could not be calculated.
OG00595.82± 35.78
ParticipantsOG0042
ParticipantsOG0055
Title
Measurements
OG00042.90± NASince only 1 participant was analyzed, SD could not be calculated.
OG001100.67± 1.15
OG002110.50± NASince only 1 participant was analyzed, SD could not be calculated.
OG003115.20± NASince only 1 participant was analyzed, SD could not be calculated.
OG00489.15± 12.52
OG005111.22± 23.82
ParticipantsOG0041
ParticipantsOG0057
Title
Measurements
OG00075.00± NASince only 1 participant was analyzed, SD could not be calculated.
OG001100.17± 8.18
OG002117.60± NASince only 1 participant was analyzed, SD could not be calculated.
OG00394.30± NASince only 1 participant was analyzed, SD could not be calculated.
OG00488.50± NASince only 1 participant was analyzed, SD could not be calculated.
OG00593.90± 15.31
ParticipantsOG0042
ParticipantsOG0059
Title
Measurements
OG000305.30± NASince only 1 participant was analyzed, SD could not be calculated.
OG00189.33± 10.45
OG00392.55± 4.17
OG004106.05± 10.25
OG005103.67± 9.40
ParticipantsOG0042
ParticipantsOG0054
Title
Measurements
OG000118.50± NASince only 1 participant was analyzed, SD could not be calculated.
OG001101.25± 1.77
OG00394.40± NASince only 1 participant was analyzed, SD could not be calculated.
OG004107.90± 9.33
OG005109.20± 23.66
Participants
OG004
2
ParticipantsOG0052
Title
Measurements
OG000108.75± 7.85
OG001134.55± 0.78
OG00393.90± NASince only 1 participant was analyzed, SD could not be calculated.